

## **Brian I. Rini, MD, FACP**

Professor of Medicine  
Leader, GU Program  
Department of Hematology and Oncology  
Cleveland Clinic Taussig Cancer Institute  
Glickman Urological and Kidney Institute  
9500 Euclid Avenue/Desk R35  
Cleveland, Ohio 44195  
Phone: 216-444-9567  
E-mail: [rinib2@ccf.org](mailto:rinib2@ccf.org)

59 Stanridge Rd.  
Chagrin Falls, OH 44022

### **PROFESSIONAL APPOINTMENTS**

Staff, Cleveland Clinic Taussig Cancer Institute Department of Solid Tumor Oncology Glickman Urological and Kidney Institute	2005 - present
Professor of Medicine Cleveland Clinic Foundation Lerner College of Medicine	2012 - present
Associate Professor of Medicine Cleveland Clinic Foundation Lerner College of Medicine	2005 - 2012
Assistant Clinical Professor of Medicine The University of California San Francisco	2001 - 2005

### **POSTGRADUATE TRAINING**

The University of Chicago Hospitals Hematology/Oncology Fellowship	1998 - 2001
The University of Chicago Hospitals Internal Medicine Residency Program	1995 - 1998

### **EDUCATION**

The Ohio State University College of Medicine Doctor of Medicine	1991- 1995
The University of Notre Dame Bachelor of Arts, Psychology	1987 - 1991

## **BOARD CERTIFICATION**

American Board of Internal Medicine	1998
American Board of Internal Medicine - Medical Oncology	2011

## **PROFESSIONAL ACTIVITIES**

<b>Oncologic Drugs Advisory Committee (ODAC)</b>	2015 - present
<b>Chair, ODAC</b>	2018 - 2019

### **Membership in Professional Organizations:**

American Society of Clinical Oncology (ASCO)	1999 - present
American Association for Cancer Research (AACR)	1999 - present
Cancer and Leukemia Group B (CALGB)	2001 - 2005
Kidney Cancer Association (KCA)	2004 - present
American Urologic Association (AUA)	2007 - present
American College of Physicians (ACP)	2007 – present
Society of Urologic Oncology (SUO)	2007 - 2013
Society of Immunotherapy of Cancer (SITC)	2014 - present

### **Service to Professional Organizations:**

#### American Society of Clinical Oncology

ASCO On-Line Committee	1999 – 2001
ASCO Fellow’s Task Force	1999 – 2001
ASCO Task Force on Associate/Junior Active Members	2001 - 2003
ASCO Education Committee: Fellows/Junior Faculty Track Track Team Leader	2003 - 2006 2003
Fellows & Junior Faculty Symposium Planning Committee	2004

ASCO Prostate Cancer Symposium: Fellows/Junior Faculty Mentoring Lunch Chairman	2004 - 2005
ASCO Board of Experts	2005 – present
ASCO Annual Meeting Program Committee Genitourinary Track Team Leader	2008 - 2010 2009
Best of ASCO Program Committee	2009
ASCO Cancer Progress Website (Cancer.net) RCC Specialty Editor Associate Editor for GU Cancers	2010 – present 2015 – present
ASCO/AACR Methods in Clinical Cancer Research Workshop Faculty	2011 - 2015

#### National Cancer Institute

National Cancer Institute Progress Review Group Kidney/Bladder Cancer	2001
The Cancer Therapy Evaluation Program (CTEP) External Review Board	2005 - present
Co-Chair, Renal Cell Carcinoma Task Force	2012 - 2014
Reviewer, Cancer Clinical Investigator Team Leadership Award	2012
NCI GU Steering Committee	2015 - present

#### Kidney Cancer Association

KCA Medical Advisory Board	2005 - 2013
KCA Annual Meeting Planning Committee	2008-2010, 2014-2016

#### American Association for Cancer Research (AACR)

Kure It Grants for Kidney Cancer Research Scientific Review Committee	2012
--	------

AACR Clinical and Translational Cancer Research Grants Scientific Review Committee	2014, 2015
<u>VHL Family Alliance Task Force Member</u>	2012 - 2015
<u>Society of Immunotherapy of Cancer (SITC)</u>	
Regional Immunotherapy Conference Organizing Committee	2013
Advances in Cancer Immunotherapy Planning Committee member	2014 - present
Vice Chair Advances in Cancer Immunotherapy Subcommittee	2016 – present
Chair, Clinical Immunotherapy Guidelines for RCC	2015 - present
<u>American Urologic Association (AUA)</u>	
Peer reviewer for the AUA’s Follow-Up to Renal Cancer guideline	2013
<u>American Joint Committee on Cancer (AJCC) Kidney/Urinary Tract Panel Member</u>	2014
<b>Service to Cleveland Clinic:</b>	
Leader, CASE Comprehensive Cancer Center Genitourinary Program	2009 - 2018
Director, Experimental Therapeutics Program	2008 – present
United Way Physician Champion	2017
Advisory Committee for the Translational Research Shared Resource	2017 - present
Chair, Medical Innovations Workshop	2014
Chair, Taussig Cancer Institute Database Committee	2011 - 2014
CCHS Pharmacy and Therapeutics Committee	2011 - 2016
Medical Editor, Cancer Consult	2007 - present
CASE Comprehensive Cancer Center Institutional Review Board	2005 - 2012

Associate Director for Clinical Research	2007 - 2009
FastTrac Project to reduce chemotherapy wait time	2006
Cleveland Clinic Foundation Regional Cancer Center Consortium for the Biological Therapy of Cancer: Planning Committee	2007
Search Committee, Chair, Department of Urology	2007, 2009
Top 10 Medical Innovations Workshop Participant	2007, 2014
Human Biospecimen Resource Committee	2007 - 2008
Referring MD Communication Project	2009
Cleveland Clinical and Translational Sciences Collaborative Scientific Review Committee	2009 – 2010
Chair, Cleveland Clinic Foundation Anatomic & Clinical Pathology Internal Review Board	2009
Member, VeloSano Planning Committee	2014, 2015
Internal Medicine Residency Interview Committee	2012 - 2015

### **Service to Professional Publications:**

Section Editor: Genitourinary Disease: <i>Cancer</i>	2008 - 2011
Editorial Board Member: <i>Lancet Oncology (2010-2013), Journal of Clinical Oncology, Cancer Research, Clinical Genitourinary Cancer; Kidney Cancer Journal; British Journal of Urology, HemOnc Today, Annals of Oncology</i>	
Ad Hoc Reviewer: <i>Journal of Clinical Oncology, Cancer, Clinical Cancer Research, Oncology, Journal of Urology, Lancet, Lancet Oncology, Expert Review of Anti-cancer Therapy, Future Oncology, Urologic Oncology, The Oncologist, Clinical Genitourinary Cancer, J Immunotherapy, Journal of Surgical Oncology, Journal of Cytokine Research, Science</i>	

### **Service to Other Cancer Centers**

Dana Farber/Harvard Cancer Center External Advisory Board	2010
---	------

## AWARDS

Eugene P. Schonfeld Career Achievement Award (KCA)	2015
Sam and Maria Miller Professional Excellence Award (Clinical Research)	2011
ASCO/AACR Workshop on Methods in Clinical Cancer Research Merrill J. Egorin Outstanding Mentor Award	2011
Case Comprehensive Cancer Center Program Leader of the Year	2011
Solid Tumor Oncology Teacher of the Year	2011-2012
CCF Department of Molecular Cardiology Page Award for Best Publication	2012
Cleveland's Best Doctors	2006-2018
CCF Research Programs Council Award Project: Immunoregulatory Effects of Cyclooxygenase-2 (COX-2) Expression in Renal Cell Carcinoma	2006, 2007
Department of Defense: New Investigator Award: CTLA-4 Blockade Based Immunotherapy in Prostate Cancer	2004
Illinois Medical Oncology Society. Best Submitted ASCO Abstract Award	2001
ASCO Abstract Merit Award: Rini BI et al.: Allogeneic Stem Cell Transplantation of Metastatic RCC after Non-myeloablative Chemotherapy	2001
ASCO/AACR Methods in Clinical Cancer Research workshop participant	1999

## BIBLIOGRAPHY

### Original Articles / Peer-Reviewed Publications:

258. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, **Rini BI**, Garcia J, Auchus RJ, Sharifi N. HSD3B1 (1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. *J Clin Invest*. 2018 Jun 25. pii: 98319. doi: 10.1172/JCI98319
257. Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, **Rini BI**, Gilligan T, Kyriakopoulos C, Garcia JA. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. *Prostate*. 2018 Jun 7. doi: 10.1002/pros.23663.
256. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, **Rini BI**, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018 Jun;24(6):749-757. doi: 10.1038/s415910180053-3.
255. **Rini BI**, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ. Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. *Clin Genitourin Cancer*. 2018 May 4. pii: S1558-7673(18)30136-8. doi: 10.1016/j.clgc.2018.04.005.
254. Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K, Tyler A, Martin A, Gilligan T, Grivas P, Ornstein M, Garcia JA, Powles T, **Rini BI**. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. *Br J Cancer*. 2018 Jul;119(2):160-163. doi: 10.1038/s41416-018-0104-z.
253. **Rini BI**, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A. Validation of the 16-Gene Recurrence Score in patients with locoregional, high-risk renal cell carcinoma from a phase 3 trial of adjuvant sunitinib. *Clin Cancer Res*. 2018 May 17. pii: clincanres.0323.2018. doi: 10.1158/1078-0432.CCR-18-0323.
252. **Rini BI**. Current and emerging first-line systemic therapies in clear cell renal cell carcinoma. *Clin Adv Hematol Oncol*. 2018 Feb;16(2):115-117.

251. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, **Rini BI**. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. *J Clin Oncol*. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485.
250. Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, **Rini BI**, Garcia JA, Grivas P. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. *Target Oncol*. 2018 Jun;13(3):353-361. doi: 10.1007/s11523-018-0561-6.
249. Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, **Rini BI**, Garcia JA, Grivas P. Myeloid-derived suppressors cells (MDSC) correlate with clinic opathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. *Urol Oncol*. 2018 Mar 29. pii: S1078-1439(18)30075-9. doi: 10.1016/j.urolonc.2018.02.018.
248. Emamekhoo H, Dhillon P, Gopalakrishnan D, Elson P, Stephenson A, Magi-Galluzzi C, McKenney J, Harper H, Haber GP, Kaouk J, Lee B, Fergany A, Berglund R, Gong M, Stein R, Krishnamurthi V, Gilligan T, Ornstein M, **Rini BI**, Garcia J, Grivas P. Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2018 Feb 6. pii: S1558-7673(18)30073-9. doi: 10.1016/j.clgc.2018.01.014.
247. Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, **Rini BI**. Preliminary results for avelumab plus azitinib as first-line therapy in patients with advanced clear – cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. *Lancet Oncol*. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4
246. **Rini BI**. Golsilocks Dosing of TKIs: A Dose that is Just Right Leads to Optimal Outcomes. *Clin Cancer Res*. 2018 Jul 1;24(13):2979-2980. doi: 10.1158/1078-0432.CCR-18-0291.
245. Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, **Rini BI**. Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated with Vascular Endothelial Growth Factor Receptor Inhibitors. *Clin Genitourin Cancer*. 2018 Jun;16(3):e663-e667. doi: 10.1016/j.clgc.2017.12.014



244. Schmidinger M, Danesi R, Jones R, McDermott R, Pyle L, **Rini BI**, Négrier S. Individualized dosing with axitinib: rationale and practical guidance. *Future Oncol*. 2017 Dec 21. doi: 10.2217/fon-2017-0455.
243. Courtney KD, Infante JR, Lam ET, Figlin RA, **Rini BI**, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 $\alpha$  Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. *J Clin Oncol*. 2017 Dec 19: JCO2017742627. doi: 10.1200/JCO.2017.74.2627.
242. Mendiratta P, **Rini BI**, Tendulkar RD. Organ Preservation for Recurrent Urethral Adenocarcinoma with Concurrent Chemotherapy and Radiation. *Urology*. 2017 Dec 2. pii: S0090-4295(17)31236-0. doi: 10.1016/j.urology.2017.11.033
241. Almassi N, Gill BC, **Rini BI**, Fareed K. Management of the small renal mass. *Transl Androl Urol*. 2017 Oct; 6(5):923-930. doi: 10.21037/tau.2017.07.11. Review.
240. Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, Puchowicz M, Serra D, Herrero L, **Rini BI**, Campbell S, Welford SM. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. *Nat Commun*. 2017 Nov 24;8(1):1769. doi: 10.1038/s41467-017-01965-8.
239. Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, **Rini BI**, Grivas P. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. *Clin Genitourin Cancer*. 2017 Oct 17. pii: S1558-7673(17)30311-7. doi: 10.1016/j.clgc.2017.10.005.
238. McDonald ML, Lane BR, Jimenez J, Lee HJ, Yim K, Bindayi A, Hamilton ZA, Field CA, Bloch AS, Dey S, Noyes S, McKay R, Millard F, **Rini BI**, Campbell SC, Derweesh IH. Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors with or Without Neoadjuvant Sunitinib: A Multicenter Analysis. *Clin Genitourin Cancer*. 2017 Sep 25. pii: S1558-7673(17)30282-3. doi: 10.1016/j.clgc.2017.09.007.
237. Barata PC, **Rini BI**. Treatment of renal cell carcinoma: Current status and future directions. *CA Cancer J Clin*. 2017 Nov;67(6):507-524. doi: 10.3322/caac.21411. Epub 2017 Sep 29. Review.
236. Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, **Rini BI**, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma. *J Clin Oncol*. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

235. Mendiratta P, **Rini BI**, Ornstein MC. Emerging immunotherapy in advanced renal cell carcinoma. *Urol Oncol*. 2017 Dec;35(12):687-693. doi: 10.1016/j.urolonc.2017.08.011. Epub 2017 Sep 8. Review.
234. Mouracade P, Chavali JS, Kara O, Dagenais J, Maurice MJ, Nelson RJ, **Rini BI**, Kaouk JH. Imaging strategy and outcome following partial nephrectomy. *Urol Oncol*. 2017 Nov;35(11): 660.e1-660.e8. doi: 10.1016/j.urolonc.2017.06.052. Epub 2017 Aug 31.
233. Mouracade P, Dagenais J, Chavali JS, Kara O, Nelson RJ, Maurice MJ, Reese J, **Rini BI**, Kaouk JH. Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy. *Clin Genitourin Cancer*. 2017 Jul 26. pii: S1558-7673(17)30216-1. doi: 10.1016/j.clgc.2017.07.019.
232. Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, Campbell SC, **Rini BI**, Derweesh IH. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. *Urol Oncol*. 2018 Jan;36(1):31-37. doi: 10.1016/j.urolonc.2017.07.015. Epub 2017 Aug 10. Review.
231. Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, **Rini BI**, Hoang C, Lin X, Escudier B. Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. *Clin Genitourin Cancer*. 2017 Jun 20. pii: S1558-7673(17)30171-4. doi: 10.1016/j.clgc.2017.06.005.
230. Hammers HJ, Plimack ER, Infante JR, **Rini BI**, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. *J Clin Oncol*. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.
229. Apellániz-Ruiz M, Diekstra MH, Roldán JM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Swen JJ, Böhringer S, García-Donás J, **Rini BI**, Guchelaar HJ, Rodríguez-Antona C. Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. *Pharmacogenet Genomics*. 2017 Jun;27(6):227-231. doi: 10.1097/FPC.0000000000000280.
228. **Rini BI**, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE. Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. *Target Oncol*. 2017 Jun;12(3):333-340. doi: 10.1007/s11523-017-0487-4.
227. Oya M, Tomita Y, Fukasawa S, Shinohara N, Habuchi T, **Rini BI**, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Uemura H. Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. *Cancer Sci*. 2017 Jun;108(6):1231-1239. doi: 10.1111/cas.13232. Epub 2017 May 22.

226. De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, **Rini BI**, Broom R, Yamamoto H, Kaymakcalan MD, Heng DY, Choueiri TK. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.
225. Hirbod-Mobarakeh A, Gordan HA, Zahiri Z, Mirshahvalad M, Hosseinverdi S, **Rini BI**, Rezaei N. Specific immunotherapy in renal cancer: a systematic review. *Ther Adv Urol*. 2017 Feb;9(2):45-58. doi: 10.1177/1756287216681246. Epub 2016 Dec 19. Review.
224. Zargar H, Almassi N, Kovac E, Ercole C, Remer E, **Rini BI**, Stephenson A, Garcia JA, Grivas P. Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. *Bladder Cancer*. 2017 Jan 27;3(1):57-63. doi: 10.3233/BLC-160080.
223. Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, **Rini BI**. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. *J Clin Oncol*. 2017 Jun 1;35(16):1764-1769. doi: 10.1200/JCO.2016.71.1184. Epub 2017 Jan 23
222. Voss MH, Bhatt RS, Plimack ER, **Rini BI**, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins M. The DART Study: Results from the dose-escalation and expansion cohorts evaluating the combination of dalantercept plus axitinib in advanced renal cell carcinoma. *Clin Cancer Res*. 2016 Dec 28. pii: clincanres.2395.2016. doi: 10.1158/1078-0432.CCR-16-2395.
221. **Rini BI**, Vogelzang NJ. Future Challenges for Drug Development in Renal Cell Carcinoma. *J Clin Oncol*. 2016 Dec 19: JCO2016710673.
220. Donskov F, Heng DY, **Rini BI**. On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis? *Expert Rev Anticancer Ther*. 2016 Dec 20:1-3. doi: 10.1080/14737140.2017.1269605.
219. Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, **Rini BI**, Guchelaar HJ. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. *Oncotarget*. 2016 Nov 25. doi: 10.18632/oncotarget.13597.
218. **Rini BI**, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. *J Immunother Cancer*. 2016 Nov 15; 4:81.

217. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, **Rini BI**, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. *Cancer Immunol Res.* 2016 Nov;4(11):948-958.
216. Najjar YG, Rayman PA, Jia X, Pavicic PG, **Rini BI**, Tannenbaum CS, Ko J, Haywood S, Cohen PA, Hamilton T, Diaz Montero CM, Finke JH. Myeloid derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL-1 $\beta$ , IL-8, CXCL5 and Mip-1 $\alpha$ . *Clin Cancer Res.* 2016 Oct 31. pii: clincanres.1823.2015.
215. Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, **Rini BI**, Lee JL, Choueiri TK, Heng DY. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. *Eur Urol.* 2016 Oct 19. pii: S0302-2838(16)30687-X. doi: 10.1016/j.eururo.2016.09.047.
214. **Rini BI**, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T. IMA901, a multi-peptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. *Lancet Oncol.* 2016 Nov;17(11):1599-1611. doi: 10.1016/S1470-2045(16)30408-9.
213. Zahoor H, **Rini BI**. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. *Expert Opin Emerg Drugs.* 2016 Dec;21(4):431-440.
212. Ornstein MC, **Rini BI**. Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology? *Clin Cancer Res.* 2016 Dec 1;22(23):5626-5628
211. Ornstein MC, Wood L, Elson P, Allman K, Beach J, Martin A, Gilligan T, Garcia JA, **Rini BI**. Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2016 Aug 18. pii: S1558-7673(16)30248-8. doi: 10.1016/j.clgc.2016.08.014.
210. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, **Rini BI**, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *J Clin Oncol.* 2016 Sep 6. pii: JCO667311.

209. Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, **Rini BI**, Chen Y, Bair AH, Ozono S, Naito S, Akaza H. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. *Jpn J Clin Oncol*. 2016 Aug 29.
208. Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, Finke JH, **Rini BI**, Lindner DJ. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. *Br J Cancer*. 2016 Oct 11;115(8):920-928. doi: 10.1038/bjc.2016.263.
207. **Rini BI**, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. *Lancet Oncol*. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6.
206. Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, Bjarnason GA, Lee JL, Sim HW, Sliwczynsk A, Ptak-Chmielewska A, Teter Z, Beuselinck B, Wood LA, Yuasa T, Pezaro C, **Rini BI**, Szczylik C, Choueiri TK, Heng DY. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur J Cancer*. 2016 Sep; 65:102-8. doi: 10.1016/j.ejca.2016.06.016.
205. Khor LY, Dhakal HP, Jia X, Reynolds JP, McKenney JK, **Rini BI**, Magi-Galluzzi C, Przybycin CG. Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma: A Study of 842 Consecutive Cases From a Single Institution. *Am J Surg Pathol*. 2016 Sep;40(9):1224-31. doi: 10.1097/PAS.0000000000000690.
204. Miller JA, Balagamwala EH, Angelov L, Suh JH, **Rini BI**, Garcia JA, Ahluwalia M, Chao ST. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. *J Neurosurg Spine*. 2016 Dec;25(6):766-774
203. Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, **Rini BI**, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanavaras R, Choueiri TK, Heng DY. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol*. 2017 Feb;71(2):204-209. doi: 10.1016/j.eururo.2016.05.049.
202. Hutson TE, Thoreson GR, Figlin RA, **Rini BI**. The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. *Am Soc Clin Oncol Educ Book*. 2016;35:113-7. doi: 10.14694/EDBK\_158892. Review.
201. George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, **Rini BI**. Safety and Efficacy of Nivolumab in Patients With

- Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.
200. **Rini BI**, Tomita Y, Melichar B, Ueda T, Grünwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2016 Dec;14(6):499-503. doi: 10.1016/j.clgc.2016.04.005.
199. Kara O, Maurice MJ, Zargar H, Malkoc E, Akca O, Andrade HS, Ramirez D, Caputo PA, Nelson RJ, **Rini BI**, Kaouk JH. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. *Int Urol Nephrol.* 2016 Aug;48(8):1253-60. doi: 10.1007/s11255-016-1314-z.
198. **Rini BI**. Changing Landscape of Refractory Renal Cell Carcinoma. *J Oncol Pract.* 2016 May;12(5):422-3. doi: 10.1200/JOP.2016.012112. No abstract available.
197. Khosravan R, Motzer RJ, Fumagalli E, **Rini BI**. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. *Clin Pharmacokinet.* 2016 Oct;55(10):1251-69. doi: 10.1007/s40262-016-0404-5.
196. Ornstein MC, **Rini BI**. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. *Expert Rev Anticancer Ther.* 2016 Jun;16(6):577-84. doi: 10.1080/14737140.2016.1184980.
195. Koshkin VS, **Rini BI**. Emerging therapeutics in refractory renal cell carcinoma. *Expert Opin Pharmacother.* 2016 Jun;17(9):1225-32. doi: 10.1080/14656566.2016.1182987.
194. Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, **Rini BI**, Jonasch E. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. *BMC Cancer.* 2016 Mar 29; 16:254. doi: 10.1186/s12885-016-2282-5.
193. Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D, **Rini BI**, Staehler MD, Ravaud A, Lin W, O'Keeffe B, Wang Y, Lu S, Spoerke JM, Huw LY, Byrtek M, Zhu R, Ware JA, Motzer RJ. Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients with Metastatic Renal Cell Carcinoma. *J Clin Oncol.* 2016 May 10;34(14):1660-8. doi: 10.1200/JCO.2015.64.8808.
192. Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, **Rini BI**, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, Choueiri TK, Heng DY. Change in

Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. *Eur Urol*. 2016 Aug;70(2):358-64. doi: 10.1016/j.eururo.2016.02.033.

191. Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, **Rini BI**, Morris MJ, Taplin ME, George D; Alliance for Clinical Trials in Oncology. A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). *EBioMedicine*. 2015 Sep 8;2(11):1814-20. doi: 10.1016/j.ebiom.2015.09.012.
190. Kwiatkowski DJ, Choueiri TK, Fay AP, **Rini BI**, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen EM, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DY, Gray KP, Signoretti S. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. *Clin Cancer Res*. 2016 May 15;22(10):2445-52. doi: 10.1158/1078-0432.CCR-15-2631.
189. Parekh H, Griswold J, **Rini BI**, Axitinib for the treatment of metastatic renal cell carcinoma. *Future Oncol*. 2016 Feb;12(3):303-11. doi: 10.2217/fon.15.322.
188. Zhao B, Wood LS, James K, **Rini BI**. Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? *Case Rep Oncol Med*. 2015; 2015:817578. doi: 10.1155/2015/817578. Epub 2015 Oct 13.
187. Donskov F, Michaelson MD, Puzanov I, Davis MP, Bjarnason GA, Motzer RJ, Goldstein D, Lin X, Cohen DP, Wiltshire R, **Rini BI**. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. *Br J Cancer*. 2015 Oct 22. doi: 10.1038/bjc.2015.368.
186. Choueiri TK, Escudier B, Powles T, Mainwaring PN, **Rini BI**, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma *N Engl J Med*. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.
185. Chen Y, **Rini BI**, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. *Target Oncol*. 2015 Sep 24.
184. Diekstra MH, Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, **Rini BI**, Guchelaar HJ. . Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients

- with metastatic renal cell carcinoma. *Eur J Clin Pharmacol*. 2015 Dec;71(12):1477-84. doi: 10.1007/s00228-015-1935-7. Epub 2015 Sep 21
183. Parekh H, **Rini BI**. Emerging therapeutic approaches in renal cell carcinoma. *Expert Rev Anticancer Ther*. 2015 Sep 17:1-10.
182. **Rini BI**, Escudier B, Hariharan S, Roberts WG, Tarazi J, Rosbrook B, Askerova Z, DeAnnuntis LL, Motzer RJ. Clin Genitourin Cancer. Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. 2015 Dec;13(6):540-547.e7. doi: 10.1016/j.clgc.2015.07.001. Epub 2015 Jul 20.
181. Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, **Rini BI**, Schmidinger M, Sternberg C, Putora PM. *Oncologist*. Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. 2015 Sep;20(9):1028-35. doi: 10.1634/theoncologist.2015-0145. Epub 2015 Aug 3.
180. Porta C, Gore ME, **Rini BI**, Escudier B, Hariharan S, Charles LP, Yang L, DeAnnuntis L, Motzer RJ. Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. *Eur Urol*. 2015 Jul 24. pii: S0302-2838(15)00610-7. doi: 10.1016/j.eururo.2015.07.006.
179. **Rini BI**, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. "Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial." *Target Oncol*. 2015 Mar;10(1):45-53. doi: 10.1007/s11523-014-0307-z. Epub 2014 Mar 5.
178. Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, **Rini BI**, Kutikov A. "Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity." *Eur Urol*. 2015 Jan;67(1):85-97. doi: 10.1016/j.eururo.2014.04.029. Epub 2014 May 21.
177. Chen Y, **Rini BI**, Bair AH, Mugundu GM, Pithavala YK. "Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma." *Clin Pharmacokinet*. 2015 Apr;54(4):397-407. doi: 10.1007/s40262-014-0207-5.
176. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, **Rini BI**. "Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium." *Clin Genitourin Cancer*. 2015 Apr;13(2):e79-85. doi: 10.1016/j.clgc.2014.08.011. Epub 2014 Sep 23.



175. Motzer RJ, **Rini BI**, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. “Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.” *J Clin Oncol*. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.
174. Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, **Rini BI**, Choueiri TK, Heng DY. “Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.” *Clin Genitourin Cancer*. 2015 Apr;13(2):150-5. doi: 10.1016/j.clgc.2014.09.003. Epub 2014 Oct 2.
173. Gowrishankar B, Przybycin CG, Ma C, Nandula SV, **Rini BI**, Campbell S, Klein E, Chaganti RS, Magi-Galluzzi C, Houldsworth J. “A genomic algorithm for the molecular classification of common renal cortical neoplasms: development and validation.” *J Urol*. 2015 May;193(5):1479-85. doi: 10.1016/j.juro.2014.11.099. Epub 2014 Dec 11.
172. Lane BR, Derweesh IH, Kim HL, O'Malley R, Klink J, Ercole CE, Palazzi KL, Thomas AA, **Rini BI**, Campbell SC. “Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.” *Urol Oncol*. 2015 Mar;33(3):112.e15-21. doi: 10.1016/j.urolonc.2014.11.009. Epub 2014 Dec 19.
171. Kalra S, **Rini BI**, Jonasch E. “Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.” *Ann Oncol*. 2015 Jan 26. pii: mdv030.
170. **Rini BI**. “Toward individualized treatment in urologic oncology.” *Urol Oncol*. 2015 Apr;33(4):170. doi: 10.1016/j.urolonc.2014.10.005. Epub 2015 Feb 4.
169. Halabi S, **Rini BI**, Escudier B, Stadler WM, Small EJ. “Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?” *Cancer*. 2015 Jun 1;121(11):1906. doi: 10.1002/cncr.29252. Epub 2015 Feb 11.
168. Ko JJ, Xie W, Kroeger N, Lee JL, **Rini BI**, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY. “The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.” *Lancet Oncol*. 2015 Mar;16(3):293-300. doi: 10.1016/S1470-2045(14)71222-7. Epub 2015 Feb 12.
167. **Rini BI**, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V. “Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.” *Ann Oncol*. 2015 Feb 20. pii: mdv103.

166. **Rini BI**, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, Gilligan T, Garcia J, Zhang Z, Kaouk J, Krishnamurthi V, Stephenson AJ, Fergany A, Klein EA, Uzzo RG, Chen DY, Campbell SC. "A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma." *J Urol*. 2015 Mar 23. pii: S0022-5347(15)03398-4. doi: 10.1016/j.juro.2015.03.096.
165. Escudier B, **Rini BI**, Motzer RJ, Tarazi J, Kim S, Huang X, Rosbrook B, English PA, Loomis AK, Williams JA. "Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma." *Clin Genitourin Cancer*. 2015 Feb 21. pii: S1558-7673(15)00033-6. doi: 10.1016/j.clgc.2015.02.007.
164. Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, **Rini BI**, Guchelaar HJ. "CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma." *Eur Urol*. 2015 Apr 27. pii: S0302-2838(15)00320-6. doi: 10.1016/j.eururo.2015.04.018.
163. **Rini BI**, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain; Jill Clancy, Kongming Wang, Andreas G. Niethammer, Subramanian Hariharan, Pfizer, New York, NY; and Bernard Escudier, Institut Gustave Roussy, Villejuif, France. Commentary on: "Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial." *Urol Oncol*. 2015 Apr 30. pii: S1078-1439(15)00122-2. doi: 10.1016/j.urolonc.2015.03.014.
162. **Rini BI**, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, Svedman C, Martini JF, Williams JA, Verkarre V, Radulescu C, Neuzillet Y, Hemmerlé I, Timsit MO, Tsiatis AC, Bonham M, Leuret T, Mejean A, Escudier B. "A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies." *Lancet Oncol*. 2015 May 12. pii: S1470-2045(15)70167-1. doi: 10.1016/S1470-2045(15)70167-1.
161. Toni K. Choueiri, Ulka Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea L. Harzstark, Ronald M. Bukowski, **Brian I. Rini**, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin H. Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert Ross, Peter Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, and Ramaprasad Srinivasan. "Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients with Papillary Renal Cell Carcinoma." *JCO* Jan 10, 2013:181-186;
160. Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, **Rini BI**. "Cessation of vascular endothelial growth factor-targeted therapy in patients

- with metastatic renal cell carcinoma: Feasibility and Clinical Outcome.” *Cancer*. 2011 Dec 2. doi: 10.1002/cncr.26666.
159. **Rini BI**, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. “Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial.” *Lancet*. 2011 Dec 3;378(9807):1931-9.
  158. Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, **Rini BI**, Staehler M, Sternberg CN, Stief CG. “Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?” *Eur Urol*. 2012 Feb;61(2):307-16.
  157. Garcia JA, **Rini BI**. “Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead.” *Cancer*. 2011 Oct 28. doi: 10.1002/cncr.26582.
  156. **Rini BI**. “Targeted therapy for patients with renal-cell carcinoma.” *Lancet Oncol*. 2011 Nov;12(12):1085-7. Epub 2011 Oct 17. PMID: 22015058
  155. Smith, A.D., Shah, S.N., **Rini, B.I.**, Likeber, M.L., Remer, E.M. “Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis.” *Urol Oncol*. 2011 Sep 26.
  154. **Rini, B.I.**, Campbell, S.C., Zhou, M. “Malignant angiomyolipoma: a rare entity with unusual biology.” *Oncology (Williston Park)*. 2011 Aug; 25(9):840-1.
  153. Kim, J.J., Vaziri, S.A., **Rini, B.I.**, Elson, P., Garcia, J.A., Wirka, R., Dreicer, R., Ganapathi, M.K., Ganapathi, R. “Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.” *Cancer*. 2011 Aug 31. doi:1002/cncr.26491.
  152. **Rini BI**, Cohen DP, Dongrui L, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ. “Hypertension as a Biomarker of Efficacy in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib” *Journal of the National Cancer Institute* May 4;103(9):763-73, 2011
  151. Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, **Rini BI**. “Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon- $\alpha$  in patients with metastatic renal cell carcinoma.” *BJU Int*. 2011 Jan 18. PMID: 21244601
  150. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, **Rini BI**, Ko JS, Cohen PA, Finke JH, Storkus WJ. “Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.” *Int J Cancer*. 2010 Dec 17. PMID:

21170961

149. Karam JA, **Rini BI**, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. "Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma." *J Urol*. 2011 Feb;185(2):439-44. Epub 2010 Dec 17. PMID: 21167518
148. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, **Rini BI**. "Sunitinib rechallenge in metastatic renal cell carcinoma patients." *Cancer*. 2010 Dec 1;116(23):5400-6. PMID: 21105118
147. Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, **Rini BI**, Choueiri TK. "Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy." *Cancer*. 2010 Nov 18. PMID: 21089096
146. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, **Rini BI**, Heng DY. "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." *J Urol*. 2011 Jan;185(1):60-6. Epub 2010 Nov 12. PMID: 21074201
145. Basappa NS, Elson P, Golshayan AR, Wood L, Garcia JA, Dreicer R, **Rini BI**. "The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib." *Cancer*. 2010 Oct 19. PMID: 20960527
144. **Rini BI**, Stein M, Shannon P, Eddy S, Tyler A, Stephenson JJ Jr, Catlett L, Huang B, Healey D, Gordon M. "Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma." *Cancer*. 2010 Oct 4. PMID: 20922784
143. Garcia JA, Mekhail T, Elson P, Triozzi P, Nemecek C, Dreicer R, Bukowski RM, **Rini BI**. "Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial." *BJU Int*. 2010 PMID: 20840548
142. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemecek C, Dreicer R, Bukowski RM, **Rini BI**. "Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab." *Cancer*. 2010 Dec 1;116(23):5383-90. 2010 Aug 30. PMID: 20806321
141. Varella L, **Rini BI**. "Emerging drugs for renal cell carcinoma." *Expert Opin Emerg Drugs*. 2010 Sep;15(3):343-53.
140. Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, **Rini B**. "Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency." *Ann*

- Oncol. 2010 Aug;21(8):1618-22.
139. Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, **Rini BI**, Garcia JA. "A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma." *Invest New Drugs*. 2010 Aug 14.
  138. Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, **Rini BI**, Heng DY. "Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy." *Urology*. 2010 Aug;76(2):430-4.
  137. Mackenzie MJ, **Rini BI**, Elson P, Schwandt A, Wood L, Trinkhaus M, Bjarnason G, Knox J. "Temsitrolimus in VEGF-refractory metastatic renal cell carcinoma." *Ann Oncol*. 2010 Jul 1.
  136. **Rini BI**, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R. "Toxicity of sunitinib plus bevacizumab in renal cell carcinoma." *J Clin Oncol*. 2010 Jun 10;28(17): e284-5.
  135. **Rini BI**. "Biomarkers: Hypertension Following Anti-Angiogenesis Therapy." *Clin Adv Hematol Oncol*. 2010 Jun; 8(6):415-6.
  134. Kim JJ, **Rini BI**, Hansel DE. "Von Hippel Lindau syndrome." *Adv Exp Med Biol*. 2010; 685:228-49.
  133. Smith AD, Shah SN, **Rini BI**, Lieber M, Remer EM. "Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy." *AJR Am J Roentgenol*. 2010 Jun;194(6):1470-8.
  132. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, **Rini B**, Finke JH, Cohen PA. "Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained." *Cancer Res*. 2010 May 1;70(9):3526-36.
  131. **Rini BI**, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. "Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206." *J Clin Oncol*. 2010 May 1; 28(13):2137-43.
  130. Seliger B, Massa C, **Rini B**, Ko J, Finke J. "Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors." *Trends Mol Med*. 2010 Apr;16(4):184-92.
  129. Dreicer R, Garcia J, Hussain M, **Rini B**, Vogelzang N, Srinivas S, Somer B, Zhao YD, Kania M, Raghavan D. "Oral enzastaurin in prostate cancer: A two-cohort phase II trial

- in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.” *Invest New Drugs*. 2010 Apr 6.
128. Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, **Rini BI**. “Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.” *BJU Int*. 2010 Mar 23.
  127. **Rini BI**. “New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.” *Clin Cancer Res*. 2010 Mar 1;16(5):1348-54.
  126. Huang D, Ding Y, Zhou M, **Rini BI**, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT. “Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.” *Cancer Res*. 2010 Feb 1;70(3):1063-71.
  125. Hudes GR, Berkenblit A, Feingold J, Atkins MB, **Rini BI**, Dutcher J. “Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.” *Semin Oncol*. 36 Suppl 3: S26-36, 2009.
  124. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, **Rini BI**, Choueiri TK. “Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.” *J Clin Oncol*. 27(34):5794-9, 2009.
  123. Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M, Rayman P, **Rini B**, Gill I, Tannenbaum CS, Finke JH. “Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction.” *J Immunol*. 183(8):5050-8, 2009.
  122. **Rini BI**, Atkins MB. “Resistance to targeted therapy in renal-cell carcinoma.” *Lancet Oncol*. 10(10):992-1000, 2009
  121. **Rini BI**, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. “A phase I study of sunitinib plus bevacizumab in advanced solid tumors.” *Clin Cancer Res*. 15(19):6277-83, 2009.
  120. **Rini BI**, Wilding G et al.: “Phase II Study of Axitinib in Sorafenib-Refractory metastatic renal cell carcinoma.” *J Clin Oncol*, 2009 Sep 20; 27(27):4462-8.
  119. Thomas AA, **Rini BI**, Stephenson AJ. et al. ”Surgical resection of renal cell carcinoma

- after targeted therapy.” J Urol 182(3):881-6, 2009.
118. **Rini BI**. “Metastatic renal cell carcinoma: many treatment options, one patient.” J Clin Oncol 27(19):3225-34, 2009.
  117. **Rini BI**. “Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.” Cancer 115(10 suppl):2306-12, 2009.
  116. **Rini BI**, Atkins MB, Bukowski RM. “Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference.” Cancer 115(10 suppl):2247-51, 2009.
  115. **Rini BI**. “Circulating tumor cells in metastatic castration-resistant prostate cancer.” Curr Oncol Rep 11(3):163-4, 2009.
  114. **Rini BI**, Dreicer R. “Management of side-effects associated with sunitinib therapy for patients with renal cell carcinoma.” OncoTargets and Therapy 2 51-61, 2009.
  113. Sa G, Das T, **Rini BI**, Finke JH. “GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells.” Cancer Res., 2009.
  112. Ko JS, Zea AH, **Rini BI**. “Sunitinib mediates reversal of myeloid-derived suppressor Cell accumulation in renal cell carcinoma patients.” Clin Cancer Res 16(6):2148-57, 2009.
  111. **Rini BI**, Campbell SC, Escudier B. “Renal cell carcinoma.” Lancet 373:1119-32.
  110. **Rini BI**, Fong L, Kwek SS. “Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.” Cancer 69(2):609-15, 2009.
  109. **Rini BI**, Heng DY, Chi KN. “A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.” Cancer 115(4):776-83, 2009.
  108. Thomas AA, **Rini BI**, Campbell SC. “Integration of surgery and systemic therapy in the management of metastatic renal cancer.” Curr Urol Rep 10(1):35-41, 2009.
  107. Thomas AA, **Rini BI**, Lane BR. “Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.” Journal of Urology 181(2):518-23; discussion 523, 2009.
  106. **Rini BI**, Golshayan AR, Garcia JA. et al.: “Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.” Journal of Clinical Oncology 27(2):235-41, 2009.

105. Finke JH, **Rini BI**, Ireland J. “Sunitinib reverses type-1 immune suppression and Decreases T-regulatory cells in renal cell carcinoma patients.” *Clinical Cancer Research* 14(20):6674-82, 2008.
104. Zhou M, Kort E, Hoekstra P, **Rini BI**, Lane B. “Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence.” *American Journal of Surgical Pathology* 33(1):72-78, 2008.
103. **Rini BI**. “Update on the use of mTOR inhibitors in renal cell carcinoma.” *Clin Adv Hematol Oncol*, 6(10):722-4, 2008.
102. Knight D, Peterson AC, **Rini BI**, Harlin H. “The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.” *Prostate*, 2008.
101. **Rini BI**, Halabi S, Rosenberg JE, Stadler WM. “Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.” *Journal of Clinical Oncology*, 26(33):5422-8, 2008.
100. Aydin H, Magi-Galluzzi C, Lane B, **Rini BI**, Zhou M. “Renal angiomyolipoma: Clinico-pathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association.” *American Journal of Surgical Pathology*, 2008.
99. George S, Dreicer R, Au JJ, **Rini BI**, Roman S. “Phase 1/11 trial of 5-fluorouracil and a non-cytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.” *Clinical Genitourinary Cancer*, 6(2):79-85, 2008.
98. **Rini BI**, Flaherty K. “Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.” *Urology Oncology*, 26(5):543-9, 2008.
97. Vakkalanka BK, **Rini BI**. “Targeted therapy in renal cell carcinoma.” *Current Opinions in Urology*, 18(5):481-7, 2008.
96. **Rini BI**, Michaelson MD, Rosenberg JE, Bukowski RM. “Anti-tumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.” *Journal of Clinical Oncology*, 26(22):3743-8, 2008.
95. Choueiri TK, Vaziri SA, **Rini BI**, Jaeger E., Von Hippel-Landau “Gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.” *Journal of Urology*, 180(3): 860-5; discussion 865-6, 2008.
94. **Rini BI**, Choueiri TK, Elson P, Khasawneh MK. “Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.” *Cancer*, 113(6): 1309-14, 2008.
93. Campbell SC, **Rini BI**, Uzzo RG. “RCC – Progress in the management of small renal



- masses and advanced disease.” AUA News, pages 4-7, 2008.
92. Hansel DE, **Rini BI**. “Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities.” *Expert Review, Anticancer Ther* 8(6):895-905, 2008.
  91. **Rini BI**, Bukowski RM. “Targeted therapy for metastatic renal cell carcinoma: a homerun or a work in progress?” *Oncology* 22(4):388-96, 2008.
  90. Sonpavde G, Hutson TE, **Rini BI**. “Axitinib for renal cell carcinoma.” *Expert Opinion Investig Drugs*, 17(5):741-8, 2008.
  89. **Rini BI**, Rathmell WK, Godley P. “Renal cell carcinoma.” *Curr Opin Oncol* 20(3):300-6, 2008.
  88. Das T, Sa G, Bukowski RM, **Rini BI**. “GM1 and tumor necrosis factor-alpha, over-expressed in renal cell carcinoma, synergize to induce T-cell apoptosis.” *Cancer Res* 68(6):2014-23, 2008.
  87. **Rini BI**. “Temsirolimus, an inhibitor of mammalian target of rapamycin.” *Clin Cancer Res* 14(5):1286-90, 2008.
  86. Choueiri TK, Bukowski RM, Plantade A, Elson P, **Rini BI**. “Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.” *Journal of Clinical Oncology*. 26(1):127-31, 2008.
  85. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, **Rini BI**, Bukowski RM. “Antitumor effects of Sunitinib or Sorafenib in patients with renal cell carcinoma who received prior antiangiogenic therapy.” *Journal of Urology*. Nov 2007.
  84. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liao KF, Freddo J, Trask PC, Kim S, **Rini BI**. “Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: A Phase II Study.” *Lancet Oncol*. 8(11):975-84, Epub Nov 2007.
  83. Tamaskar I, Bukowski RM, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, **Rini BI**. “Thyroid function test abnormalities in patients with renal cell Carcinoma treated with Sorafenib.” *Ann Oncol*. Oct 2007
  82. **Rini BI**. “Sunitinib.” *Expert Opinion Pharmacother*. 8(14):2359-69, Oct 2007.
  81. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, **Rini BI**, Bukowski RM. “Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.” *Cancer*. 110(3):543-50, 2007.

80. Tamaskar I, Choueiri TK, Sercia L, **Rini BI**, Bukowski R, Zhou M. “Differential expression of caveolin-1 in renal neoplasms.” *Cancer*. Jun 26, 2007.
79. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, **Rini BI**, Michaelson MD, Motzer RJ. “Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.” *J Transl Med*. Jul 2; 5(1):32, 2007.
78. Lin AM, **Rini BI**, Kakefuda M, Weinberg V, Randall M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ: “A Phase I Trial of Estramustine, Docetaxel and Imatinib Mesylate in Hormone Refractory Prostate Cancer Patients.” *Clin Genitourin Cancer*. (5):323-8, 2007.
77. **Rini BI**, Campbell SC. “The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.” *J Urol*. 177(6):1978-84, 2007.
76. **Rini BI**, McDermott D, Atkins M. “What is standard initial systemic therapy in metastatic renal cell carcinoma?” *Clin Genitourin Cancer*. 5(4):256-63, 2007.
75. Cohen D, Lane B, Jin T, Magi-Galluzzi C, Finke J, **Rini BI**, Bukowski RM, Zhou M. “The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation.” *Clin Genitourin Cancer* 5(4):264-70, 2007.
74. Rathmell WK, Martz CA, **Rini BI**. “Renal cell carcinoma.” *Curr Opin Oncol* 19(3):234-40, 2007.
73. McDermott, DF, **Rini BI**. “Immunotherapy for metastatic renal cell carcinoma.” *BJU Int*. 99(6):1282-8, 2007.
72. Garcia JA and **Rini BI**. “Recent progress in the management of advanced renal cell carcinoma.” *CA Cancer J Clin*. 57(2):112-25, 2007.
71. **Rini BI**. “Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions.” *Clinical Cancer Research* 13(4):1098-106, 2007.
70. Lane BR, **Rini BI**, Novick AC, Campbell SC. “Targeted Molecular Therapy for Renal Cell Carcinoma.” *Urology* 69(1):3-10, 2007.
69. Unnithan J and **Rini BI**. “The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma.” *TSW Urology* 2; 74-81, 2007.
68. Small EJ, Tchekmedyian SN, **Rini BI**, Fong L, Lowy I, Allison JP. “A Phase I Trial of CTLA-4 Blockade with Human Anti-CTLA-4 (MDX-010) in Patients with Hormone Refractory Prostate Cancer.” *Clinical Cancer Research* 13(6): 1810-5, 2007.

67. Choueiri TK, **Rini BI**, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. “Prognostic Factors Associated with Long-Term Survival in Previously Untreated Metastatic Renal Cell Carcinoma.” *Annals of Oncology* 18: 249-255, 2007.
66. **Rini BI**, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski, RM. “Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib.” *Journal of the National Cancer Institute* 99(1): 81-83, 2007.
65. **Rini BI**. “Targeted Therapy in Renal Cell Carcinoma: Where Do We Go From Here?” *Expert Review of Anticancer Therapy* (12): 1753-60, 2006.
64. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Lineham WM, McDermott DF, Ochoa AC, Pantuck AJ, **Rini BI**, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. “Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference.” *Clinical Cancer Research* 13(2): 667s-70s, 2007.
63. **Rini BI**, Rathmell WK. “Biologic Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma.” *Clinical Cancer Research* 13(2): 741s-6s, 2007.
62. George S, **Rini BI**. “Therapeutic Considerations in Patients with Metastatic Renal Cell Carcinoma Previously Treated with Antiangiogenic Therapies.” *Clinical Genitourinary Cancer* 1: S40-4, 2006.
61. Choueiri TK, **Rini BI**, Dreicer R, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Elson P, Bukowski RM. “Phase II Study of Lenalidomide (Revlimid) in Patients with Metastatic Renal Cell Carcinoma.” *Cancer* 107(11): 2609-16, 2006.
60. Reddy GK, Mughal TI, **Rini BI**. “Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced-Stage Renal Cell Carcinoma.” *Clinical Genitourinary Cancer* 5(2): 110-3, 2006.
59. Stadler WM, Halabi S, **Rini BI**, Ernstoff MS, Davila E, Picus J, Barrier R, Small E. “A Phase II Study of Gemcitabine and Capecitabine in Metastatic Renal Cancer: A Report of Cancer and Leukemia Group B Protocol 90008.” *Cancer* 107(6): 1273-79, 2006.
58. Choueiri TK, Bukowski RM, **Rini BI**. “The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma.” *Seminars in Oncology* 33(5): 596-606, 2006.
57. **Rini BI**, Shaw V, Rosenberg JE, Kim Sindy T, Chen I. “Patients with Metastatic Renal Cell Carcinoma with Long-Term Disease-Free Survival after Treatment with Sunitinib and Resection of Residual Metastases.” *Clinical Genitourinary Cancer* 5(3): 232-4, 2006.

56. **Rini BI**, Campbell SC, Rathmell WK. “Renal Cell Carcinoma.” *Current Opinion in Oncology* 18(3): 289-296, 2006.
55. **Rini BI**. “Current status and future directions of molecular markers in renal cell carcinoma.” *Current Opinion in Urology*; 16(5): 332-6, 2006.
54. **Rini BI**. “Sorafenib.” *Expert Opinion Pharmacotherapy* 7(4): 453-61, 2006.
53. **Rini BI**. “VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.” *Current Oncology Report* 8(2): 85-9, 2006.
52. Lin AM, **Rini BI**, Small EJ. “Clinical trials in patients with biochemically relapsed prostate cancer.” *British Journal of Urology* 97: 905-10, 2006.
51. Lin AM, **Rini BI**, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. “A Phase II Trial of Imatinib Mesylate in Patients with Biochemical Relapse of Prostate Cancer after Definitive Local Therapy.” *British Journal of Urology* 98(4): 763-9, 2006.
50. Shaheen PE, **Rini BI**, Bukowski RM. “Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.” *Clinical Genitourinary Cancer* 5(1): 78-81, 2006.
49. Motzer RJ, **Rini BI**, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg, Bacik J, Kim ST, Baum CM, Michaelson MD: “Pivotal Study of Sunitinib Malate (SU11248) Shows Efficacy in Patients with Metastatic Renal Cell Carcinoma.” *JAMA* 295(21): 2516-24, 2006.
48. **Rini BI**, Halabi S, Barrier R, Margolin K, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ: “Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study.” *Blood and Bone Marrow Transplant* 12(7): 778-85, 2006.
47. **Rini BI**, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ: “Combination Immunotherapy with APC8015 Plus Bevacizumab in Patients with Serologic Progression of Prostate Cancer After Definitive Local Therapy.” *Cancer* 107(1): 67-74, 2006.
46. **Rini BI**, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM: “Clinical Response to VEGF-targeted Therapy in Metastatic Renal Cell Carcinoma: Impact of Patient Characteristics and VHL Gene Mutation.” *British Journal of Urology* 98(4): 756-62, 2006.
45. Eisenberg MS, Stoller ML, Master VA, Meng MV, **Rini BI**, Carroll PR, Kane CJ. “Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma.” *J Endourology* 20(7): 504-8, 2006.

44. **Rini BI**, Fong L, Weinberg V, Kavanaugh B and Small EJ. "Clinical and Immunologic Characteristics of Patients with Serologic Progression of Prostate Cancer Achieving Long-term Disease Control with GM-CSF." *Journal of Urology* 295(21): 2516-24, 2006.
43. **Rini BI**, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, and Small EJ. "Maximal COX-2 Immunostaining and Clinical Response to Celecoxib and Interferon Alpha Therapy in Metastatic Renal Cell Carcinoma." *Cancer* 106(3): 566-75, 2006.
42. **Rini BI**. "SU11248 and AG013736: Current Data and Future Trials in Renal Cell Carcinoma." *Clinical Genitourinary Cancer* 4(3): 175-80, 2005.
41. Webster SW, Small EJ, Kwon E and **Rini BI**. "Prostate Cancer Immunology: Biology, Therapeutics and Challenges." *Journal of Clinical Oncology* 23(32): 8262-9, 2005.
40. Rathmell K, Wright T, **Rini BI**. "Molecularly targeted therapy in renal cell carcinoma." *Expert Rev. Anticancer Therapy* 5(6): 1-10, 2005.
39. **Rini BI**. "Inhibiting the VEGF signaling pathway: New trials focus on combination therapy with antiangiogenic agents." *Kidney Cancer Journal* 3(1): 20-24, 2005.
38. Motzer RJ, Michaelson MD, Redman BG, Hudes GO, Wilding G, Figlin RA, Ginsberg MS, Kim S, Baum C, DePrimo S, Li J, Bello C, Theuer C, George D, **Rini BI**. "Multi-targeted Tyrosine Kinase Inhibitor SU11248 Shows a High Level of Antitumor Activity in Patients with Metastatic Renal Cell Carcinoma." *Journal of Clinical Oncology* 24(1): 1-8, 2005.
37. **Rini BI**, Beinart G, Weinberg VW, Small EJ. "APC8015 (Provenge®) in Patients with Androgen-dependent, Biochemically-relapsed Prostate Cancer." *Clinical Prostate Cancer* 4(1): 55-60, 2005.
36. Rathmell K, Godley P, **Rini BI**. "Renal Cell Carcinoma." *Current Opinion in Oncology* 17(3): 261-267, 2005.
35. **Rini BI**, Sosman JA, Motzer RJ. "VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma: Biology, Clinical Results and Future Development." *British Journal of Urology* 96(3): 286-290, 2005.
34. Stadler WM, Rosner G, Small E, Hollis D, **Rini BI**, Zaentz SD, Mahoney J, Ratain MJ. "Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma: CALGB 69901." *Journal of Clinical Oncology* 23(16): 3726-32, 2005.
33. **Rini BI**, Small EJ. "Biology and Clinical Development of VEGF-Targeted Therapy in

- Renal Cell Carcinoma.” *Journal of Clinical Oncology*; 23(5): 1-16, 2005.
32. **Rini BI**. “New Approaches in Advanced Renal Cell Carcinoma.” *Urologic Oncology: Seminars and Original Investigations* 23(1): 65-66, 2005.
  31. Artz AA, Van Beisen K, Zimmerman T, Gajewski TF, **Rini BI**, Hu HS, Stadler WM, Vogelzang NJ. “Long-term Follow Up of Non-myeloablative Allogeneic Stem Cell Transplantation for Renal Cell Carcinoma: The University of Chicago Experience.” *Blood and Bone Marrow Transplant* 35(3): 253-60, 2005.
  30. **Rini, BI**, Wadhwa, M, Bird, C, Small ES, Gaines-Das R, Thorpe R. “Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived GM-CSF.” *Cytokine* 29(2): 56-66, 2005.
  29. **Rini BI**, Weinberg VW, Small EJ. “A Phase I Trial of Fixed Dose Rate Gemcitabine and Capecitabine in Metastatic Renal Cell Carcinoma.” *Cancer* 103(3): 553-558, 2005.
  28. **Rini BI**. “Recent Clinical Development of Dendritic Cell-based Immunotherapy for Prostate Cancer.” *Expert Opin Biol Therapy* (11): 1729-34, 2004.
  27. Oh WK, Kantoff PW, Weinberg V, Jones G, **Rini BI**, Derynck MK, Bok R, Smith MR, Bublej GJ, Rosen RT, DiPaola RS, Small EJ. “A prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPEs, and diethylstilbestrol in patients with androgen-independent prostate cancer.” *Journal of Clinical Oncology* 22(18): 3705-12, 2004.
  26. **Rini BI**. “Vascular Endothelial Growth Factor as a Therapeutic Target in Metastatic Renal Cell Carcinoma.” *Biologic Therapy of Cancer* 2(2): 11-14, 2004.
  25. **Rini BI**, Weinberg V, Shaw V, Bok RA, Park JW, Small EJ. “Time to Disease Progression to Evaluate a Novel Protein Kinase C Inhibitor (UCN-01) in Renal Cell Carcinoma.” *Cancer* 101(1): 90-5, 2004.
  24. Small EJ, Halabi S, Dawson NA, Stadler WM, **Rini BI**, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. “Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).” *Journal of Clinical Oncology* 22(6): 1025-33, 2004.
  23. **Rini BI**, Halabi S, Taylor J, Small ES and. Schilsky RL. “CALGB 90206: A Randomized Phase III Trial of Interferon-alpha or Interferon-alpha Plus anti-VEGF Antibody (bevacizumab, Avastin®) in Metastatic Renal Cell Carcinoma.” *Clinical Cancer Research* 10(8): 2584-6, 2004.
  22. **Rini BI**, Weinberg V and Small EJ. “Practice and Progress in Kidney Cancer: Methodology for Novel Drug Development.” *J Urology* 171(6): 2115-21, 2004.

21. Harlin H, Artz AS, Mahowald M, **Rini BI**, Zimmerman T, Vogelzang NJ, Gajewski TF. "Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells." *Bone Marrow Transplant* 33(5): 491-7, 2004.
20. **Rini BI**, Weinberg V, Bok R and Small EJ. "PSA Kinetics as a Measure of the Biologic Effect of GM-CSF in Patients with Serologic Progression of Prostate Cancer." *Journal of Clinical Oncology* 21(1): 99-105, 2003.
19. **Rini BI**, Small EJ. "The Potential for Prostate Cancer Immunotherapy." *Critical Reviews in Oncology and Hematology* 27(46 Suppl):117-25, 2003.
18. **Rini BI**, Paintal A, Vogelzang NJ, Gajewski TF and Stadler WM. "Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity." *J Immunotherapy* 25(3): 269-77, 2002.
17. **Rini BI**, Zimmerman TZ, Stadler WM, Gajewski TF and Vogelzang NJ. "Allogeneic Stem Cell Transplantation of Renal Cell Cancer After Non-myeloablative Chemotherapy: Feasibility, Engraftment and Clinical Results." *Journal of Clinical Oncology* 20(8): 2017-2024, 2002.
16. Desai AA, Vogelzang NJ, **Rini BI**, Ansari R, Krauss S, Stadler WM. "A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." *Cancer* 95(8): 1629-36, 2002.
15. **Rini BI**. "Technology evaluation: APC-8015." *Current Opinion in Molecular Therapeutics* 4(1): 76-79, 2002.
14. **Rini BI**, Small EJ. "Prostate Cancer Update." *Curr Opin Oncology* 14(3): 286-91, 2002.
13. **Rini BI**, Scott T. and Small EJ. "Docetaxel, Estramustine Plus Trastuzumab in Patients with Metastatic, Androgen-Independent Prostate Cancer." *Physician's Education Resource*.
12. **Rini BI**, Small EJ. "Current Treatment of Hormone-Refractory Prostate Cancer." *Curr Treatment Options Oncology* 3(5): 437-46, 2002.
11. George CM, Vogelzang NJ, **Rini BI**, Stadler WM. "A Phase II Trial of Weekly Intravenous Gemcitabine and Cisplatin with Prolonged Continuous Infusion 5-Fluorouracil in Patients with Metastatic Renal Cell Carcinoma." *Annals of Oncology* 13(1): 116-20, 2002.
10. **Rini BI** and Small EJ. "An Update on Prostate Cancer." *Current Opinion in Oncology*

- 13(3): 204-211, 2001.
9. **Rini BI** and Small EJ. "Immunotherapy for prostate cancer." *Current Oncology Reports* 3(5): 418-23, 2001.
  8. **Rini BI** and Small EJ. "Anti-tumor effects of GM-CSF in prostate cancer." *Immune-Enhancing Cytokines* 3(1): 5-7, 2001.
  7. Citow JS, **Rini BI**, Wollmann R and Macdonald RL. "Isolated, primary extra nodal Hodgkin's disease of the spine: case report." *Neurosurgery* 49(2): 453-6, 2001.
  6. **Rini BI**, Zimmerman TZ, Gajewski TF, Stadler WM and Vogelzang NJ. "Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma." *J Urology* 165(3): 1208-9, 2001.
  5. **Rini BI**, Vogelzang NJ, Dumas M, Wade III JL, Taber DA, and Stadler WM. "Phase II trial of gemcitabine and continuous infusion fluorouracil in patients with metastatic renal cell cancer." *Journal of Clinical Oncology* 18(12): 2419-26, 2000.
  4. **Rini BI**, Vogelzang NJ. "Prognostic factors in renal carcinoma." *Seminars in Oncology* 27(2): 213-220, 2000.
  3. **Rini BI**, Gajewski TF. "Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with Octreotide." *Annals of Oncology* 10(8): 973-979, 1999.
  2. **Rini BI**, Selk LM, Vogelzang NJ. "Phase I study of direct intralesional transfer of HLA-B7 into metastatic renal carcinoma lesions." *Clinical Cancer Research* 5(10): 2766-2772, 1999.
  1. **Rini BI**, Stadler WM, Spielberger RT, Ratain MJ, and Vogelzang NJ. "Granulocyte-macrophage colony stimulating factor in metastatic renal cell carcinoma: a phase II trial." *Cancer* 82(7): 1352-1358, 1998.



## Book Chapters and Editorial Comments

25. Campbell SC, **Rini BI**, Zhang Z, Zhao J: Neoadjuvant therapy to downsize tumor and enable partial nephrectomy, GUKI Research Notes, published June, 2015, available at: <http://consultqd.clevelandclinic.org/2015/06/preserving-kidney-function-in-renal-cell-carcinoma/>.
24. **Rini BI**, Campbell SC. Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma. *JAMA Oncol.* 2015 May;1(2):212-3. doi: 10.1001/jamaoncol.2015.0262
23. R.A. Figlin, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA; W.K. Rathmell, University of North Carolina, Chapel Hill, NC, USA; **B.I. Rini**, Cleveland Clinic Taussig Cancer Institute, OH, USA (Eds.): *Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets*. Springer Science, Human Press, New York, NY. March 2012.
22. Khaled Ali, Ming Zhou, Steve Campbell, Ronald M. Bukowski and **Brian I. Rini**: Uncommon Tumors of the Kidney: *Textbook of Uncommon Cancer*, Fourth Edition. Edited by Derek Raghavan, Charles D. Blanke, David H. Johnson, Paul L. Moots, Gregory H. Reaman, Peter G. Rose and Mikkael A. Sekeres. 2012 John Wiley & Sons, Inc. Published 2012 by John Wiley & Sons, Inc.
21. Campbell SC, **Rini BI**, Editors: *Renal Cell Carcinoma: Clinical Management*. Springer Science, Human Press, New York, NY. October 2012.
20. **Rini B.** “Kidney cancer: Does hypothyroidism predict clinical outcome?” *Nat Rev Urol.* 2011 Jan;8(1):10-1. PMID: 21116300
19. **Rini BI**, Shah SN. Editorial comment. *Urology.* 2010 May;75(5):1114-5
18. Campbell SC, **Rini BI**. Editorial Comment. *J Urol.* 182(6):2599-600, 2009
17. **Rini BI**, Hurwitz M. Urothelial and kidney cancers. “Cancer Management: A Multi-Disciplinary Approach.” 11th Edition, Chapter 19, 2009.
16. Garcia JA, **Rini BI**. Biochemical recurrence of prostate cancer. In: Dahut WL, Gulley JL, Moul JW, Sandler HM, eds. *Prostate Cancer: A Clinical Guide*. Philadelphia, Penn: Lippincott, Williams, & Wilkins; Chapter 12. 2008.
15. **Rini BI**. “Lapatinib therapy for patients with advanced renal cell carcinoma.” *Nat Clin Prac Oncol*, 5(11):626-7, 2008.
14. **Rini BI**. “Quantifying hypertension in patients with cancer treated with sorafenib.” *Lancet Oncol.* 9(2):86-7, 2008.

13. **Rini BI.** “Commentary: Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma?” *Nat Clin Prac Urol.* 5(3):132-3, 2008.
12. Linehan M, **Rini BI** and Yang JC. Kidney Cancer. In *Cancer: Principles & Practice of Oncology*. 8th edition. Editors, Drs. Vincent DeVita, Theodore Lawrence, and Steven Rosenberg, 2007.
11. **Rini BI.** Sorafenib in advanced renal cancer. *Drugs* 67(3); 484-5, 2007.
10. **Rini BI.** Guest Commentary on: Stabilization of disease in patients with Metastatic Renal Cell Carcinoma using Sorafenib. *Nature Clinical Practice Oncology* 3(11): 602-03, 2006.
9. **Rini BI.** Guest Commentary on Sorafenib in Advanced Renal Cancer. *Adis Drug Profile. American Journal of Cancer*, 2006; 5(2).
8. **Rini BI, Sandler HM, Wood DP.** Management of Hormone-Sensitive Non-Metastatic Prostate Cancer. Report to the Nation on Prostate Cancer: Focus on Advanced Disease 2005 Professional Edition.
7. Brown CK, **Rini BI, Connell PP,** editors. *Holland-Frei Manual of Cancer Medicine*. Hamilton: BC Decker Inc; 2005.
6. **Rini BI, Ward J, Vogelzang NJ.** Primary Neoplasms of the Kidney and Renal Pelvis. *Diseases of the Kidney and Urinary Tract* 8th edition. Lippincott Williams and Wilkins.
5. **Rini BI.** Practice Point Commentary on Mekahil et al. Validation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. *Nature Clinical Practice Oncology* 2(5):2-3, 2005.
4. **Rini BI, Vogelzang NJ:** Commentary re: Yang JC et al. A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. *American Journal of Oncology Review.* 3(8): 8-10, 2004.
3. **Rini BI, Vogelzang NJ:** Adjuvant Hormonal Therapy for Prostate Cancer, in D’Amico A, Carroll P, Kantoff PW (Eds): *Prostate Cancer*. Philadelphia, PA, Lippincott, Williams & Wilkins. 464-473, 2002.
2. **Rini BI, Torti FM and Small ES:** Kidney Cancer, in Dollinger M: *Everyone’s Guide to Cancer Therapy*. Kansas City, MO, Andrews McMeel, 582-588, 2002.
1. **Rini BI, Vogelzang NJ:** Editorial comments on Management of renal carcinoma. *Oncology* 14(1): 29-35, 2000.

## Abstracts

213. **Brian I. Rini**, Thomas Powles, Mei Chen, Markus Puhmann, Michael B. Atkins; “Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naïve advanced/metastatic renal cell carcinoma (mRCC).” *J Clin Oncol* 35, 2017 (suppl; abstr TPS4597)
212. Eric Jonasch, Rebecca Slack, Daniel M. Geynisman, Matthew I. Milowsky, Kimryn Rathmell, Summer Stovall, Donna Juarez, Elizabeth R. Plimack, Nizar M. Tannir, **Brian I. Rini**; “Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carcinoma.” *J Clin Oncol* 35, 2017 (suppl; abstr 4513)
211. Haris Zahoor, Paul G Pavicic, Christopher Przybycin, Paul Elson, C. Marcela Diaz-Montero, James Finke, Patricia A. Rayman, Timothy D. Gilligan, Petros Grivas, Moshe Chaim Ornstein, Jorge A. Garcia, **Brian I. Rini**; “T cell infiltration (TCI) in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC).” *J Clin Oncol* 35, 2017 (suppl; abstr 4587)
210. Waddah Arafat, Charlotte Stahlfeld, Jamie M Sperger, Erika Heninger, Dharmesh Gopalakrishnan, Pedro C. Barata, Marcelo Lamenza, Sarah Devonshire, Nita Hoxha, Pam Profusek, **Brian I. Rini**, Moshe Chaim Ornstein, Jorge A. Garcia, Christos Kyriakopoulos, Joshua Michael Lang, Petros Grivas; “Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.” *J Clin Oncol* 35, 2017 (suppl; abstr 4537)
209. Vadim S. Koshkin, Pedro C. Barata, Nicholas J. Vogelzang, Sumanta K. Pal, Joann Hsu, Kimberly D Allman, Timothy D. Gilligan, **Brian I. Rini**; “Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.” *J Clin Oncol* 35, 2017 (suppl; abstr 4586)
208. Toni K. Choueiri, **Brian I. Rini**, James M. G. Larkin, Georg A. Bjarnason, Gwenaelle Gravis, Howard Gurney, Jae-Lyun Lee, Daniel Keizman, John B. A. G. Haanen, Yoshihiko Tomita, Hirotsugu Uemura, Laurence Albiges, Manuela Schmidinger, Michael B. Atkins, Mariangela Mariani, Michael Shnaidman, Alessandra di Pietro, Robert J. Motzer; “Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).” *J Clin Oncol* 35, 2017 (suppl; abstr TPS4594)
207. Bernard J. Escudier, **Brian I. Rini**, Jean-Francois Martini, Wayne Yen-Hwa Chang, Jan Breza, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D. Goddard, Patricia A English, Rachel Li, Xun Lin, Olga Valota, Giacomo Carteni, Michael D. Staehler, Robert J. Motzer, Alain Ravaud; “Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients.” *J Clin Oncol* 35, 2017 (suppl; abstr 4508)

206. Robert Uzzo, Axel Bex, **Brian I. Rini**, Laurence Albiges, Cristina Suarez, Frank Donaldson, Takashi Asakawa, Christina Schiff, Sumanta K. Pal; “A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010).” J Clin Oncol 35, 2017 (suppl; abstr TPS4598)
205. Moshe Chaim Ornstein, C. Marcela Diaz-Montero, Patricia A. Rayman, Paul Elson, Samuel Haywood, Jin Sub Kim, Paul G Pavicic, James Finke, **Brian I. Rini**, Andrew J. Stephenson, Marcelo Lamenza, Priscilla Dann, Kim Schach, Sarah Devonshire, Jennifer S Ko, Amr Farouk Fergany, Marc S. Ernstoff, Christopher J. Hoimes, Jorge A. Garcia, Petros Grivas; “Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC).” J Clin Oncol 35, 2017 (suppl; abstr 4548)
204. **Brian I. Rini**, Thomas E. Hutson, Robert A. Figlin, Mariajose Lechuga, Olga Valota, Lucile Serfass, Michelle Casey, Robert J. Motzer; “Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group.” J Clin Oncol 35, 2017 (suppl; abstr 4584)
203. Vadim S. Koshkin, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse McKenney, Karen Streator Smith, Bonnie Shadrach, Kumiko Isse, Laura R. Saunders, Ming Hu, Rahul D. Tendulkar, Andrew J. Stephenson, Amr Farouk Fergany, Mohamed Abazeed, **Brian I. Rini**, Jorge A. Garcia, Byron Lee, Omar Y Mian, Petros Grivas; “Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype.” J Clin Oncol 35, 2017 (suppl; abstr 4529)
202. C. Marcela Diaz-Montero, Patricia A. Rayman, Jin Sub Kim, Paul G Pavicic, Charles Tannenbaum, Vamsidhar Velcheti, Pauline Funchain, Jennifer S Ko, Petros Grivas, **Brian I. Rini**, Alberto J. Montero, James Finke; “Flow cytometric detection of MDSC populations in unfractionated blood.” J Clin Oncol 35, 2017 (suppl 7S; abstract 56)
201. Toni K. Choueiri, James M. G. Larkin, Mototsugu Oya, Fiona C. Thistlethwaite, Marcella Martignoni, Paul D. Nathan, Thomas Powles, David F. McDermott, Paul B. Robbins, David D. Chism, Daniel C. Cho, Michael B. Atkins, Michael S. Gordon, Sumati Gupta, Hirotosugu Uemura, Yoshihiko Tomita, Anna Compagnoni, Alessandra di Pietro, **Brian I. Rini**; “First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.” J Clin Oncol 35, 2017 (suppl; abstr 4504)
200. Michael B. Atkins, David F. McDermott, Thomas Powles, Robert J. Motzer, **Brian I. Rini**, Lawrence Fong, Richard Wayne Joseph, Sumanta K. Pal, Mario Sznol, John D. Hainsworth, Walter Michael Stadler, Thomas E. Hutson, Alain Ravaud, Sergio Bracarda, Cristina Suarez, Toni K. Choueiri, Jiaheng Qiu, Mahrukh A. Huseni, Christina Schiff, Bernard J. Escudier; “IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and

- following atezo or sunitinib (sun).” J Clin Oncol 35, 2017 (suppl; abstr 4505)
199. Robert J. Motzer, Naomi B. Haas, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae-Lyun Lee, Bohuslav Melichar, **Brian I. Rini**, Toni K. Choueiri, Milada Zemanova, Lori A Wood, Dirk Fahlenkamp, Martin Neil Reaume, Arnulf Stenzl, Weichao Bao, Paola Aimone, Christian Doehn, Paul Russo, Cora N. Sternberg; “Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).” J Clin Oncol 35, 2017 (suppl; abstr 4507)
  198. Daniel J. George, Susan Halabi, Mark D. Starr, Herbert Hurwitz, John C. Brady, Ian Barak, Michael J. Morris, **Brian I. Rini**, Eric Jay Small, Won Kim, Mary-Ellen Taplin, Andrew B. Nixon; “Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).” J Clin Oncol 35, 2017 (suppl; abstr 4522)
  197. **Brian I. Rini**, Michael B. Atkins, Bernard J. Escudier, Thomas E. Hutson, Piotr Koralewski, David F. McDermott, Sumanta K. Pal, Michael N. Needle, Camillo Porta; “Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).” J Clin Oncol 35, 2017 (suppl; abstr TPS4600)
  196. Vadim S. Koshkin, Pedro C. Barata, Haris Zahoor, Lisa A. Rybicki, Hamid Emamekhoo, Nima Almassi, Katherine Tullio, Alicia M Redden, Amr Farouk Fergany, Jihad Kaouk, Georges-Pascal Haber, Jennifer Beach, Allison Martin, Kimberly D Allman, Jorge A. Garcia, Timothy D. Gilligan, **Brian I. Rini**, Petros Grivas; “Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice.” J Clin Oncol 35, 2017 (suppl 6S; abstract 390)
  195. Meena Sadaps, Haris Zahoor, Paul Elson, Hamid Emamekhoo, Kim Schach, Nicole DiBiase Brey, Jihad Kaouk, Georges-Pascal Haber, Michael C. Gong, Ryan Kent Berglund, Venkatesh Krishnamurthi, James Ulchaker, Timothy D. Gilligan, **Brian I. Rini**, Jorge A. Garcia, Petros Grivas; “Evaluation of patient (Pt), treatment, and prognostic factors in urinary tract adenocarcinoma.” J Clin Oncol 35, 2017 (suppl 6S; abstract 408)
  194. Steven Yip, Connor Wells, Raphael Brandao Moreira, Alex Wong, Sandy Srinivas, Benoit Beuselinck, Camillo Porta, Hao-Wen Sim, D. Scott Ernst, **Brian I. Rini**, Takeshi Yuasa, Naveen S. Basappa, Ravindran Kanesvaran, Lori Wood, Christina M. Canil, Anil Kapoor, Simon Yuen Fai Fu, Toni K. Choueiri, Daniel Yick Chin Heng; “Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).” J Clin Oncol 35, 2017 (suppl; abstr 4580)
  193. Brian Allen, Edward Florez, Reza Sirous, Seth T Lirette, Michael Griswold, Erick M.

- Remer, Zhen J. Wang, Jacob E Bieszczad, Kelly L Cox, Ajit H. Goenka, Candace M Howard-Claudio, HyunSeon Kang, Sadhna B Nandwana, Rupan Sanyal, Atul B. Shinagare, J. Clark Henagen, Judd Storrs, Matthew S. Davenport, **Brian I. Rini**, Andrew Dennis Smith; “Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation.” *J Clin Oncol* 35, 2017 (suppl 6S; abstract 432)
192. Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, A H. Bair, **Brian I. Rini**; Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study. *J Clin Oncol* 35, 2017 (suppl 6S; abstract 438)
191. Eric Jonasch, Rebecca Slack, Daniel M. Geynisman, Matthew I. Milowsky, Kimryn Rathmell, Summer Stovall, Donna Juarez, Elizabeth R. Plimack, Nizar M. Tannir, “A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma.” *J Clin Oncol* 35, 2017 (suppl 6S; abstract 533)
190. Vadim S. Koshkin, Paul Elson, Cristina Magi-Galluzzi, Jesse McKenney, Karen Streater Smith, Bonnie Shadrach, Hamid Emamekhoo, Kumiko Isse, Laura Saunders, Edward Kavalerchik, Scott Dylla, Sheila Bheddah, Noah Theiss, Sky Watson, Andrew J. Stephenson, Amr Farouk Fergany, **Brian I. Rini**, Jorge A. Garcia, Petros Grivas; “Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC).” *J Clin Oncol* 35, 2017 (suppl 6S; abstract 382)
189. Moshe Chaim Ornstein, C. Marcela Diaz-Montero, Patricia A. Rayman, Paul Elson, Samuel Haywood, Jin Sub Kim, Paul G Pavicic, James Finke, **Brian I. Rini**, Andrew J. Stephenson, Marcelo Lamenza, Priscilla Dann, Nicole DiBiase Brey, Sarah Devonshire, Jennifer S Ko, Amr Farouk Fergany, Marc S. Ernstoff, Christopher J. Hoimes, Jorge A. Garcia, Petros Grivas; “Assessment of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and treatment response in urothelial carcinoma (UC) patients (pts) undergoing surgery.” *J Clin Oncol* 35, 2017 (suppl 6S; abstract 362)
188. David F. McDermott, Michael B. Atkins, Robert J. Motzer, **Brian I. Rini**, Bernard J. Escudier, Lawrence Fong, Richard Wayne Joseph, Sumanta K. Pal, Mario Sznol, John D. Hainsworth, Walter Michael Stadler, Thomas E. Hutson, Alain Ravaud, Sergio Bracarda, Cristina Suarez, Toni K. Choueiri, YounJeong Choi, Mahrukh A. Huseni, Gregg Daniel Fine, Thomas Powles; “A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).” *J Clin Oncol* 35, 2017 (suppl 6S; abstract 431)
187. Igor Stukalin, Connor Wells, Anna Paola Fraccon, Felice Pasini, Camillo Porta, Raphael Brandao Moreira, Sandy Srinivas, I. Alex Bowman, James Brugarolas, Jae-Lyun Lee, Frede Donskov, Benoit Beuselinck, Aristotelis Bamias, **Brian I. Rini**, Hao-Wen Sim, Neeraj Agarwal, Sun Young Rha, Ravindran Kaneshvaran, Toni K. Choueiri, Daniel Yick

- Chin Heng; “Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).” *J Clin Oncol* 35, 2017 (suppl 6S; abstract 498)
186. Steven Yip, Connor Wells, Raphael Brandao Moreira, Alex Wong, Sandy Srinivas, Benoit Beuselinck, Camillo Porta, Hao-Wen Sim, D. Scott Ernst, **Brian I. Rini**, Takeshi Yuasa, Naveen S. Basappa, Ravindran Kanesvaran, Lori Wood, Denis Soulieres, Christina M. Canil, Anil Kapoor, Simon Yuen Fai Fu, Toni K. Choueiri, Daniel Yick Chin Heng;” Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.” *J Clin Oncol* 35, 2017 (suppl 6S; abstract 492)
185. Pedro C. Barata, Dharmesh Gopalakrishnan, Paul Elson, Vadim S. Koshkin, Moshe Chaim Ornstein, C. Marcela Diaz-Montero, Samuel Haywood, Patricia A. Rayman, James Finke, Marcelo Lamenza, Sarah Devonshire, Pam Profusek, Kimberly D Allman, Allison Martin, Jennifer Beach, Kim Schach, Timothy D. Gilligan, **Brian I. Rini**, Jorge A. Garcia, Petros Grivas; “Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).” *J Clin Oncol* 35, 2017 (suppl; abstr e16031)
184. Moshe Chaim Ornstein, C. Marcela Diaz-Montero, Patricia A. Rayman, Paul Elson, Samuel Haywood, Jin Sub Kim, Paul G Pavicic, James Finke, **Brian I. Rini**, Jihad Kaouk, Marcelo Lamenza, Priscilla Dann, Kim Schach, Sarah Devonshire, Jennifer S Ko, Georges-Pascal Haber, Marc S. Ernstoff, Christopher J. Hoimes, Jorge A. Garcia, Petros Grivas; “Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI).” *J Clin Oncol* 35, 2017 (suppl; abstr e16005)
183. Dominick Bosse, Wanling Xie, Connor Wells, Aly-Khan A. Lalani, Frede Donskov, Alisha Bent, Hao-Wen Sim, Benoit Beuselinck, Aristotelis Bamias, Camillo Porta, Ulka N. Vaishampayan, Sumanta K. Pal, Neeraj Agarwal, Sandy Srinivas, **Brian I. Rini**, Ajjai Shivaram Alva, Lori Wood, Anil Kapoor, Toni K. Choueiri, Daniel Yick Chin Heng;” Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).” *J Clin Oncol* 35, 2017 (suppl; abstr e16065)
182. Steven Yip, Jose Manuel Ruiz Morales, Frede Donskov, Anna Paola Fraccon, Umberto Basso, **Brian I. Rini**, Jae-Lyun Lee, Georg A. Bjarnason, Jennifer J. Knox, Benoit Beuselinck, Ravindran Kanesvaran, James Brugarolas, Konstantinos Koutsoukos, Simon Yuen Fai Fu, Takeshi Yuasa, Carmel Jo Pezaro, Ajjai Shivaram Alva, Christian K. Kollmannsberger, Toni K. Choueiri, Daniel Yick Chin Heng; “Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.” *J Clin Oncol* 34, 2016 (suppl; abstr 4570)
181. Jose Manuel Ruiz Morales, Marcin Swierkowski, Connor Wells, Anna Paola Fraccon, Francesca La Russa, Frede Donskov, Georg A. Bjarnason, Jae-Lyun Lee, Hao-Wen Sim,

- Benoit Beuselinck, Lori Wood, Takeshi Yuasa, Carmel Jo Pezaro, **Brian I. Rini**, Cezary Szczylik, Toni K. Choueiri, Daniel Yick Chin Heng; “First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).” *J Clin Oncol* 34, 2016 (suppl; abstr 4510)
180. Guillermo de Velasco, Wanling Xie, Frede Donskov, Laurence Albiges, Benoit Beuselinck, Sandhya Srinivas, Neeraj Agarwal, Jae-Lyun Lee, James Brugarolas, Lori Wood, Christian K. Kollmannsberger, Sun Young Rha, Scott A. North, Ravindran Kanesvaran, **Brian I. Rini**, Reuben James Broom, Haru Yamamoto, Marina Dusevic Kaymakcalan, Daniel Yick Chin Heng, Toni K. Choueiri; “Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).” *J Clin Oncol* 34, 2016 (suppl 2S; abstr 503)
179. Ian D. Davis, Wanling Xie, Carmel Jo Pezaro, Frede Donskov, Connor Wells, Neeraj Agarwal, Sandhya Srinivas, Takeshi Yuasa, Benoit Beuselinck, Lori Wood, D. Scott Ernst, Ravindran Kanesvaran, Jennifer J. Knox, Allan J. Pantuck, Sadia Saleem, Ajjai Shivaram Alva, **Brian I. Rini**, Jae-Lyun Lee, Toni K. Choueiri, Daniel Yick Chin Heng “Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.” *J Clin Oncol* 34, 2016 (suppl 2S; abstr 534)
178. Bernard J. Escudier, Robert J. Motzer, Thomas Powles, Nizar M. Tannir, Ian D. Davis, Frede Donskov, Viktor Grünwald, Daniel Yick Chin Heng, Thomas Hutson, Bohuslav Melichar, Dimitry Nosov, **Brian I. Rini**, Pamela Salman, Cora N. Sternberg, Cezary Szczylik, Pascal Wolter, Alan M Arroyo, Milan Mangeshkar, Neeraj Agarwal, Toni K. Choueiri; “Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).” *J Clin Oncol* 34, 2016 (suppl 2S; abstr 499)
177. Toni K. Choueiri, Thomas Powles, Bernard J. Escudier, Nizar M. Tannir, Paul Mainwaring, **Brian I. Rini**, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae-Lyun Lee, Daniel Yick Chin Heng, Manuela Schmidinger, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Sumanta K. Pal, Thomas E. Hutson, Robert J. Motzer “Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).” *J Clin Oncol* 34, 2016 (suppl; abstr 4506)
176. David F. McDermott, Robert J. Motzer, Michael B. Atkins, Elizabeth R. Plimack, Mario Sznol, Saby George, Charles G. Drake, **Brian I. Rini**, Toni K. Choueiri, Timothy Kuzel, Jeffrey Alan Sosman, David C. Smith, Ulka N. Vaishampayan, John D. Powderly, Suzanne Louise Topalian, Huanyu Zhao, Ian M. Waxman, Hans J. Hammers “Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal



- cell carcinoma (aRCC) from phase I and II studies.” J Clin Oncol 34, 2016 (suppl; abstr 4507)
175. Haoran Li, Nils Kroeger, Guillermo de Velasco, Frede Donskov, Hao-Wen Sim, Connor Wells, Igor Stukalin, Neeraj Agarwal, Hiral D. Parekh, **Brian I. Rini**, Jennifer J. Knox, Allan J. Pantuck, Toni K. Choueiri, Daniel Yick Chin Heng; “The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.” J Clin Oncol 34, 2016 (suppl 2S; abstr 552)
  174. Nizar M. Tannir, Robert A. Figlin, Martin Eric Gore, Dror Michaelson, Robert J. Motzer, Camillo Porta, **Brian I. Rini**, Caroline J. Hoang, Xun Lin, Bernard Escudier;” Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC).” J Clin Oncol 34, 2016 (suppl 2S; abstr 598)
  173. Hamid Emamekhoo, Puneet Dhillon, Dharmesh Gopalakrishnan, Haider Al taii, Hiral D. Parekh, Paul Elson, Jesse McKenney, Cristina Magi-Galluzzi, Holly Lynn Harper, Homi Zargar, **Brian I. Rini**, Andrew J. Stephenson, Michael C. Gong, Amr Farouk Fergany, Georges-Pascal Haber, Steven C. Campbell, Jihad Kaouk, Ryan Kent Berglund, Jorge A. Garcia, Petros Grivas; “Prognostic markers assessment in invasive upper tract urothelial carcinoma (UTUC).” J Clin Oncol 34, 2016 (suppl; abstr e16034)
  172. Hamid Emamekhoo, Dharmesh Gopalakrishnan, Puneet Dhillon, Haider Al taii, Paul Elson, Jesse McKenney, Cristina Magi-Galluzzi, Holly Lynn Harper, Homi Zargar, **Brian I. Rini**, Andrew J. Stephenson, Michael C. Gong, Amr Farouk Fergany, Georges-Pascal Haber, Steven C. Campbell, Jihad Kaouk, Ryan Kent Berglund, Robert Stein, Jorge A. Garcia, Petros Grivas “Evaluation of prognostic factors in upper tract urothelial carcinoma (UTUC).” J Clin Oncol 34, 2016 (suppl 2S; abstr 372)
  171. Petros Grivas, Hamid Emamekhoo, Paul Elson, Jesse McKenney, Homi Zargar, Cristina Magi-Galluzzi, Kim Schach, Nicole DiBiase Brey, Andrew J. Stephenson, Terri McClanahan, Jennifer Yearley, Wendy Blumenschein, Lakshmanan Annamalai, **Brian I. Rini**, Jorge A. Garcia; “PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).” J Clin Oncol 34, 2016 (suppl; abstr e16023)
  170. James M. G. Larkin, Michael S. Gordon, Fiona Thistlethwaite, Paul D. Nathan, **Brian I. Rini**, Marcella Martignoni, Michael Shnaidman, Chiara Chiruzzi, Alessandra Di Pietro, Toni K. Choueiri; “Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma” J Clin Oncol 34, 2016 (suppl; abstr TPS4580)
  169. Kevin Dale Courtney, Jeffrey R. Infante, Elaine Tat Lam, Robert A. Figlin, **Brian I. Rini**, James Brugarolas, Naseem J. Zojwalla, Keshi Wang, Eli Wallace, John A. Josey, Toni K. Choueiri;” A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor,

- in patients with advanced clear cell renal cell carcinoma.” J Clin Oncol 34, 2016 (suppl; abstr 2506)
168. Moshe Chaim Ornstein, C. Marcela Diaz-Montero, Pat A. Rayman, Paul Elson, Samuel Haywood, James Finke, Jorge A. Garcia, **Brian I. Rini**, Andrew J. Stephenson, Steven C. Campbell, Amr Farouk Fergany, Hamid Emamekhoo, Marcelo Lamenza, Sylvia Stybor, Kim Schach, Pam Profusek, Allison Janine Tyler, Marc S. Ernstoff, Petros Grivas; “Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC).” J Clin Oncol 34, 2016 (suppl 2S; abstr 434)
  167. Hamid Emamekhoo, Monali K. Vasekar, Monika Joshi, Sierra Min Li, Arnab Basu, JoAnn Hsu, Junjia Zhu, Garrett Michael Frampton, Siraj Mahamed Ali, Vincent A. Miller, Jeffrey S. Ross, **Brian I. Rini**, Jorge A. Garcia, Sumanta K. Pal, Petros Grivas ‘Correlation of genomic alterations with outcome in patients (pts) with urothelial carcinoma (UC).” J Clin Oncol 34, 2016 (suppl; abstr e16021)
  166. Moshe Chaim Ornstein, C. Marcela Diaz-Montero, Pat A. Rayman, Paul Elson, Samuel Haywood, James Finke, Jorge A. Garcia, **Brian I. Rini**, Andrew J. Stephenson, Steven C. Campbell, Amr Farouk Fergany, Hamid Emamekhoo, Marcelo Lamenza, Sylvia Miller, Kim Schach, Pam Profusek, Allison Janine Tyler, Marc S. Ernstoff, Christopher J. Hoimes, Petros Grivas; “Evaluation of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and pathologic response in urothelial carcinoma (UC).” J Clin Oncol 34, 2016 (suppl; abstr e16010)
  165. Samuel Haywood, Roy Chen, Paul Pavicic, Lin Lin, C. Marcela Diaz-Montero, Pat A. Rayman, Christopher Przybycin, James Finke, **Brian I. Rini** “Sunitinib's effect on tumor infiltration of CD8 T cells in renal cell carcinoma (RCC) and modulation of their function by altering VEGF-induced upregulation of PD1 expression.” J Clin Oncol 34, 2016 (suppl 2S; abstr 591)
  164. Vadim S Koshkin, Hamid Emamekhoo, Paul Elson, Jesse McKenney, Cristina Magi-Galluzzi, Kim Schach, Andrew J. Stephenson, **Brian I. Rini**, Jorge A. Garcia, Petros Grivas; “Patient/treatment characteristics and prognostic factors in small-cell bladder cancer (SCBC).” J Clin Oncol 34, 2016 (suppl; abstr e16037)
  163. Moshe Chaim Ornstein, Andrew J. Stephenson, Paul Elson, Allison Janine Tyler, Pam Profusek, Petros Grivas, **Brian I. Rini**, Eric A. Klein, Jorge A. Garcia; “Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).” J Clin Oncol 34, 2016 (suppl; abstr 5071)
  162. Hamid Emamekhoo, Mohammad Alyamani, Zhenfei Li, Paul Elson, Petros Grivas, **Brian I. Rini**, Marianne Petro, Sylvia Stybor, Anthony Salatino, Jorge A. Garcia, Nima Sharifi “The association of D<sup>4</sup>, 3-keto-abi (D4A) and response to abiraterone in castration-resistant prostate cancer (CRPC).” J Clin Oncol 34, 2016 (suppl 2S; abstr 245)

161. Hamid Emamekhoo, Paul Elson, Petros Grivas, William Shomali, Natasha Catherine Edwin, **Brian I. Rini**, Jorge A. Garcia; “Evaluation of response to enzalutamide (E) consecutively after disease progression on abiraterone/prednisone (AP) and potential predictors of response.” J Clin Oncol 34, 2016 (suppl 2S; abstr 294)
160. David Cunningham, Ela Plow, Didier Allexandre, **Brian I. Rini**, Mellar P. Davis; “Neurophysiological changes: Sunitinib fatigue severity” J Clin Oncol 34, 2016 (suppl; abstr e21683)
159. Daniel Yick Chin Heng, Connor Wells, Frede Donskov, **Brian I. Rini**, Jae-Lyun Lee, Georg A. Bjarnason, Benoit Beuselinck, Martin Smoragiewicz, Ajjai Shivaram Alva, Sandy Srinivas, Lori Wood, Haru Yamamoto, D. Scott Ernst, Sumanta Kumar Pal, Takeshi Yuasa, Reuben James Broom, Ravindran Kaneshvaran, Aristotelis Bamias, Jennifer J. Knox, Toni K. Choueiri; “Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.” J Clin Oncol 33, 2015 (suppl 7; abstr 430). 2015 Genitourinary Cancers Symposium.
158. Vijay Damarla, Paul Elson, Laura S. Wood, Sylvia Sybor, Pat A. Rayman, Yu Ning Wong, Elizabeth R. Plimack, James Finke, **Brian I. Rini**; “Immune cell repertoire in patients with metastatic renal cell carcinoma: Data from prospective clinical trial.” J Clin Oncol 33, 2015 (suppl 7; abstr 452). 2015 Genitourinary Cancers Symposium.
157. Martin Henner Voss, Elizabeth R. Plimack, **Brian I. Rini**, Michael B. Atkins, Robert Alter, Rupal Satish Bhatt, J. Thaddeus Beck, Kristen M. Pappas, Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi Sumant Pandya; “DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.” J Clin Oncol 33, 2015 (suppl 7; abstr 407). 2015 Genitourinary Cancers Symposium.
156. **Brian I. Rini**, Jennifer Yearly, Hari Dhakal, Christopher Przybycin; “Association of PD-1 and PD-L1 protein expression in matched primary and metastatic renal cell carcinoma tumors.” J Clin Oncol 33, 2015 (suppl 7; abstr 418). 2015 Genitourinary Cancers Symposium.
155. Nimira S. Alimohamed, Arnoud J. Templeton, Jennifer J. Knox, Xun Lin, Ronit Simantov, Wanling Xie, Nicola Jane Lawrence, Reuben James Broom, Andre Poisl Fay, **Brian I. Rini**, Georg A. Bjarnason, Martin Smoragiewicz, Christian K. Kollmannsberger, Ravindran Kaneshvaran, Connor Wells, Eitan Amir, Toni K. Choueiri, Daniel Yick Chin Heng; “Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma.” J Clin Oncol 33, 2015 (suppl 7; abstr 404). 2015 Genitourinary Cancers Symposium.
154. Moshe Chaim Ornstein, Vlado Knezevic, **Brian I. Rini**, Ulka N. Vaishampayan; “Association between primary tumor protein expression and response to sunitinib in

- patients with metastatic renal cell carcinoma.” J Clin Oncol 33, 2015 (suppl 7; abstr 450). 2015 Genitourinary Cancers Symposium.
153. Vyshak Alva Venur, Laura S. Wood, Paul Elson, Allison Martin, Jennifer Beach, Jorge A. Garcia, **Brian I. Rini**; “An alternative titration schedule of axitinib in metastatic renal cell carcinoma.” J Clin Oncol 33, 2015 (suppl 7; abstr 444). 2015 Genitourinary Cancers Symposium.
152. Davendra Sohal, **Brian I. Rini**, Robert James Pelley, Bassam N. Estfan, Dale Randall Shepard, Robert Dreicer, Brian James Bolwell, Alok A. Khorana; “Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer: Results of a prospective cohort study.” J Clin Oncol 33, 2015 (suppl 3; abstr 593). 2015 Gastrointestinal Cancers Symposium.
151. Davendra Sohal, **Brian I. Rini**, Bassam N. Estfan, Dale Randall Shepard, Michael J. McNamara, Robert Dreicer, Brian James Bolwell, Alok A. Khorana; “Challenges with genomic testing in pancreaticobiliary cancers: Results of a prospective cohort study.” J Clin Oncol 33, 2015 (suppl 3; abstr 314). 2015 Gastrointestinal Cancers Symposium.
150. Daniel Yick Chin Heng, Igor Stukalin, Connor Wells, Frede Donskov, **Brian I. Rini**, Jae-Lyun Lee, Georg A. Bjarnason, Benoit Beuselinck, Martin Smoragiewicz, Ajjai Shivaram Alva, Sandy Srinivas, Lori Wood, James Brugarolas, Sumanta Kumar Pal, Takeshi Yuasa, Reuben James Broom, Ravindran Kanavar, Aristotelis Bamias, Jennifer J. Knox, Toni K. Choueiri; “Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).” J Clin Oncol 33, 2015 (suppl; abstr e15578). 2015 ASCO Annual Meeting.
149. Haoran Li, Toni K. Choueiri, Connor Wells, Neeraj Agarwal, Frede Donskov, Jae-Lyun Lee, Reuben James Broom, Takeshi Yuasa, **Brian I. Rini**, Sumanta Kumar Pal, Lori Wood, D. Scott Ernst, Christian K. Kollmannsberger, Ulka N. Vaishampayan, Sun Young Rha, Georg A. Bjarnason, Jennifer J. Knox, Sadia Saleem, Benoit Beuselinck, Daniel Yick Chin Heng; “Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: results from the International mRCC Consortium (IMDC).” J Clin Oncol 33, 2015 (suppl; abstr 4558). 2015 ASCO Annual Meeting.
148. Andre Poisl Fay, David J. Kwiatkowski, Kathryn P. Gray, Aaron Thorner, **Brian I. Rini**, Neeraj Agarwal, Thai Huu Ho, Jiayi Song, Pablo M Barrios, Laurence Albiges, Eliezer Mendel van Allen, Katherine Margaret Krajewski, Camillo Porta, Sumanta Kumar Pal, Joaquim Bellmunt, David F. McDermott, Daniel Yick Chin Heng, Sabina Signoretti, Toni K. Choueiri; “Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.” J Clin Oncol 33, 2015 (suppl; abstr 4519). 2015 ASCO Annual Meeting.

147. Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, **Brian I. Rini**, David F. McDermott, Marc Ernstoff, Martin Henner Voss, Padmanee Sharma, Sumanta Kumar Pal, Albiruni R. A. Razak, Christian K. Kollmannsberger, Daniel Yick Chin Heng, Jennifer L. Spratlin, Yun Shen, Paul Gagnier, Asim Amin; “Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).” *J Clin Oncol* 33, 2015 (suppl; abstr 4516). 2015 ASCO Annual Meeting.
146. Elizabeth R. Plimack, Hans J. Hammers, **Brian I. Rini**, David F. McDermott, Bruce Redman, Timothy Kuzel, Michael Roger Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Allyson Margolin, Li-an Xu, Ian Waxman, Robert Motzer; “Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).” *J Clin Oncol* 33, 2015 (suppl; abstr 4553). 2015 ASCO Annual Meeting.
145. Meta Diekstra, Jesse J Swen, Epie Boven, Daniel E. Castellano, Hans Gelderblom, Ron H.J. Mathijssen, Cristina Rodriguez-Antona, Jesús García-Donas, **Brian I. Rini**, Henk-Jan Guchelaar; “*CYP3A5* and *ABCB1* polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.” *J Clin Oncol* 33, 2015 (suppl; abstr 4548). 2015 ASCO Annual Meeting.
144. Hans J. Hammers, Elizabeth R. Plimack, Cora Sternberg, David F. McDermott, James M. G. Larkin, Alain Ravaud, **Brian I. Rini**, Padmanee Sharma, Prabhu Bhagavatheeswaran, Paul Gagnier, Robert Motzer; “CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.” *J Clin Oncol* 33, 2015 (suppl; abstr TPS4578). 2015 ASCO Annual Meeting.
143. Rosa Nadal, Asim Amin, Daniel M. Geynisman, Martin Henner Voss, Matthew Weinstock, Jaime Doyle, Zhe Zhang, Antonio Viudez, Elizabeth R. Plimack, David F. McDermott, Robert Motzer, **Brian I. Rini**, Hans J. Hammers; “Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).” *J Clin Oncol* 33, 2015 (suppl; abstr 4566). 2015 ASCO Annual Meeting.
142. Martin Henner Voss, Elizabeth R. Plimack, Brian I. Rini, Michael B. Atkins, Robert Alter, Rupal Satish Bhatt, J. Thaddeus Beck, Musa Mutyaba, Kristen M. Pappas, Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi Sumant Pandya; “The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC).” *J Clin Oncol* 33, 2015 (suppl; abstr TPS4583). 2015 ASCO Annual Meeting.
141. Davendra Sohal, **Brian I. Rini**, Robert James Pelley, Bassam N. Estfan, Dale Randall Shepard, Timmy Q. Nguyen, Robert Dreicer, Brian James Bolwell, Alok A. Khorana;

- “Genomic testing enhances treatment choices and clinical trial accrual in metastatic colorectal cancer (CRC): Results of a prospective clinical study.” J Clin Oncol 33, 2015 (suppl; abstr e14631). 2015 ASCO Annual Meeting.
140. Davendra Sohal, **Brian I. Rini**, Alok A. Khorana, Robert Dreicer, Jame Abraham, Gary Procop, Yogen Sauntharajah, Nathan A. Pennell, James Stevenson, Robert James Pelley, Bassam N. Estfan, Dale Randall Shepard, Pauline Funchain, David J. Adelstein, Brian James Bolwell; “Prospective clinical study of precision oncology in solid tumors.” J Clin Oncol 33, 2015 (suppl; abstr 6585). 2015 ASCO Annual Meeting.
139. Petros Grivas, Homi Zargar, Cesar Emilio Ercole, Evan Kovac, Erick M. Remer, Wadih Karim, Hamid Emamekhoo, Andrew J. Stephenson, Amr Farouk Fergany, Michael C. Gong, Steven C. Campbell, Ryan Kent Berglund, Robert Dreicer, **Brian I. Rini**; “Assessment of sarcopenia as predictor of response and outcome after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC).” J Clin Oncol 33, 2015 (suppl; abstr e15512). 2015 ASCO Annual Meeting.
138. Martin Henner Voss, Elizabeth R. Plimack, **Brian I. Rini**, Michael B. Atkins, Robert Alter, Rupal Satish Bhatt, J. Thaddeus Beck, Musa Mutyaba, Kristen M. Pappas, Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi Sumant Pandya; “The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).” J Clin Oncol 33, 2015 (suppl; abstr 4567). 2015 ASCO Annual Meeting.
137. Pauline Funchain, Davendra Sohal, Alok A. Khorana, Jame Abraham, Nathan A. Pennell, **Brian I. Rini**, Robert Dreicer, Brian James Bolwell, Charis Eng; “Hereditary implications of somatic tumor testing.” J Clin Oncol 33, 2015 (suppl; abstr 1523). 2015 ASCO Annual Meeting.
136. Moshe Chaim Ornstein, Paul Elson, Jorge A. Garcia, Timothy D. Gilligan, Laura S. Wood, Kimberly D Allman, Allison Martin, **Brian I. Rini**; “Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.” J Clin Oncol 33, 2015 (suppl; abstr 4562). 2015 ASCO Annual Meeting.
135. **Rini BI**, Yoshihiko Tomita, Bohuslav Melichar, Takeshi Ueda, Viktor Grünwald, Mayer N. Fishman, Hirotsugu Uemura, Mototsugu Oya, A H. Bair, Glen Andrews, Dmitri Pavlov, Eric Jonasch; “Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.” J Clin Oncol 33, 2015 (suppl; abstr 4545). 2015 ASCO Annual Meeting.
134. Elizabeth R. Plimack, Cheryl Nemec, Paul Elson, Cristina Suarez, Tanya B Dorff, James M. G. Larkin, Cecilia McAleer, Isaac Nunez, Rosalie Anne Fisher, and **Brian I. Rini**; “An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy.” ASCO MEETING ABSTRACTS May 30, 2012: TPS4679

133. M. Dror Michaelson, **Brian I. Rini**, Bernard J. Escudier, Joseph Clark, Bruce Redman, Jamal Christo Tarazi, Brad Rosbrook, Sinil Kim, and Robert John Motzer; “Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients.” ASCO MEETING ABSTRACTS May 30, 2012:4546
132. Wanling Xie, Toni K. Choueiri, Jae-Lyun Lee, Lauren Christine Harshman, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Ulka N. Vaishampayan, Takeshi Yuasa, Min-Han Tan, Sun Young Rha, Frede Donskov, Neeraj Agarwal, Christian K. Kollmannsberger, Scott A. North, **Brian I. Rini**, and Daniel Yick Chin Heng; “Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.” ASCO MEETING ABSTRACTS May 30, 2012:4538.
131. Laura S. Wood, Robert Dreicer, Jorge A. Garcia, Timothy D. Gilligan, Khaled B. Ali, Housam Haddad, Shetal N. Shah, Paul Elson, and **Brian I. Rini**; “A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).” ASCO MEETING ABSTRACTS May 30, 2012: TPS4684.
130. Daniel Yick Chin Heng, Toni K. Choueiri, Jae-Lyun Lee, Lauren Christine Harshman, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Ulka N. Vaishampayan, Takeshi Yuasa, Min-Han Tan, Sun Young Rha, Frede Donskov, Neeraj Agarwal, Sumanta Kumar Pal, Christian K. Kollmannsberger, Scott A. North, **Brian I. Rini**, and Lori Wood; “An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.” ASCO MEETING ABSTRACTS May 30, 2012:4536.
129. Housam Haddad, **Brian I. Rini**, Eric Jonasch, Nizar M. Tannir, Robert Dreicer, Jorge A. Garcia, Laura S. Wood, and Paul Elson; “Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC).” ASCO MEETING ABSTRACTS May 30, 2012:4609.
128. Baidehi Maiti, Laura S. Wood, Paul Elson, Jorge A. Garcia, Robert Dreicer, Steven C. Campbell, and **Brian I. Rini**; “The association between the treatment-induced hypertension (Htn) and response to neoadjuvant sunitinib in renal cell carcinoma (RCC)”. ASCO MEETING ABSTRACTS May 30, 2012: e15095.
127. Hans J. Hammers, **Brian I. Rini**, Gary R. Hudes, Marc S. Ernstoff, Christian K. Kollmannsberger, Yun Shen, Ian Waxman, and Arindam Dhar; “A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma.” ASCO MEETING ABSTRACTS May 30, 2012: TPS2614.
126. **Rini BI**, Viktor Grunwald, Mayer N. Fishman, Bohuslav Melichar, Takeshi Ueda, Petr A Karlov, A H. Bair, Ying Chen, Sinil Kim, and Eric Jonasch; “Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.” ASCO MEETING ABSTRACTS May 30, 2012:4503.

125. Srinivasan, Ramaprasad, Bottaro, Donald P., Choueiri, Toni K., Vaishampayan, Ulka N., Rosenberg, Jonathan E., Logan, Theodore, Harzstark, Andrea Lynne, **Rini, Brian I.**, Srinivas, Sandy, Adams, Laurel M., Laubscher, Kevin, Ottesen, Lone Harild, McDermott, David F.; “Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).” 2012 Genitourinary Cancers Symposium.
124. Ali, Khaled B., Shah, Shetal N., Wood, Laura S., Garcia, Jorge A., Dreicer, Robert, Gilligan, Timothy D., **Rini, Brian I.**; “Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib.” 2012 Genitourinary Cancers Symposium.
123. Klink, Joseph C., Westesson, Karin E., **Rini, Brian I.**, Rabets, John C., Campbell, Steven C., Ghoneim, Islam, Stephenson, Andrew J., Krishnamurthi, Venkatesh; “Cytoreductive radical nephrectomy (cRN) and level II-IV inferior vena cava (IVC) thrombectomy for metastatic renal cell carcinoma (mRCC).” 2012 Genitourinary Cancers Symposium.
122. Heng, Daniel Yick Chin, Lee, Jae-Lyun, Harshman, Lauren Christine, Bjarnason, Georg A., Razak, Albiruni R., MacKenzie, Mary J., Wood, Lori, Vaishampayan, Ulka N., Tan, Min-Han, Rha, Sun Young, Donskov, Frede, Agarwal, Neeraj, Kollmannsberger, Christian K., North, Scott A., **Rini, Brian I.**, Choueiri, Toni K.; “A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).” 2012 Genitourinary Cancers Symposium.
121. Mohammadi, Alireza Mohammad, Chao, Samuel T., **Rini, Brian I.**, Garcia, Jorge A., Suh, John H., Angelov, Lilyana; “The role of stereotactic radiosurgery in the treatment of renal cell carcinoma patients with five or more brain metastases.” 2012 Genitourinary Cancers Symposium.
120. Choueiri, Toni K., Xie, Wanling, Harshman, Lauren Christine, Bjarnason, Georg A., Knox, Jennifer J., MacKenzie, Mary J., Wood, Lori, Vaishampayan, Ulka N., Tan, Min-Han, Sun Young Rha, Frede Donskov, Neeraj Agarwal, Christian K. Kollmannsberger, North, Scott A. **Rini, Brian I.**, Heng, Daniel Yick Chin; “Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the international mRCC database consortium.” 2012 Genitourinary Cancers Symposium.
119. Choueiri, Toni K., Vaishampayan, Ulka N., Rosenberg, Jonathan E., Logan, Theodore, Harzstark, Andrea Lynne, **Rini, Brian I.**, Srinivas, Sandy, Adams, Laurel M., Sherman, Laurie Jill, Ottesen, Lone Harild, McDermott, David F., Bottaro, Donald P., Linehan, W. Marston, Srinivasan, Ramaprasad; “A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary



- renal cell carcinoma: Final efficacy, safety, and PD results.” 2012 Genitourinary Cancers Symposium.
118. Heng, Daniel Yick Chin, Choueiri, Toni K. Lee, Jae-Lyun, Harshman, Lauren Christine, Bjarnason, Georg A., Knox, Jennifer J., MacKenzie, Mary J., Vaishampayan, Ulka N., Tan, Min-Han, Rha, Sun Young, Donskov, Frede, Agarwal, Neeraj, Kollmannsberger, Christian K., North, Scott A., **Rini, Brian I.**, Wood, Lori; “A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.” 2012 Genitourinary Cancers Symposium.
117. **Rini, Brian I.**, Escudier, Bernard J., Michaelson, M Dror, Negrier, Sylvie, Gore, Martin Eric, Oudard, Stephane, Clark, Joseph, Tarazi, Jamal Christo, Rosbrook, Brad, Kim, Sinil, Motzer, Robert John; “Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.” 2012 Genitourinary Cancers Symposium.
116. Heng, D.Y., MacKenzie, M.J., Vaishampayan, U.N., Knox, J.J., Bjarnason, G.A., Tan, M., Wood, L., Donskov, F., **Rini, BI**, Choueiri, K., International mRCC Consortium. “Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy.” ASCO Meeting Abstracts, March 29, 2011:299.
115. Sadeghi, S., Albiges, L., Wood, L.S., Black, S.L., Gilligan, T.D., Dreicer, R., Garcia, J.A., Escudier, B.J., **Rini, BI**; “Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome.” ASCO Meeting Abstracts, March 29, 2011:305.
114. **Rini, BI**, Szczylik, C., Tannir, N.M., Koralewski, P., Tomczak, P., Deptata, A., Kracht, K., Sun, Y., Puhlmann, M., Escudier, B.; “AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study.” ASCO Meeting Abstracts, March 29, 2011:309.
113. Khambati, H., Choueiri, T.K. Kollmannsberger, C. K., North, S., Bjarnason, G.A., Vaishampayan, U. N., Wood, L., MacKenzie, M.J., **Rini, BI**, Heng, D.Y.; International mRCC Database Consortium. “Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.” ASCO Meeting Abstracts, March 29, 2011:318.
112. Alharbi, H., Choueiri, T.K., Kollmannsberger, C.K., North, S., Mackenzie, M.J., Knox, J.J., **Rini, BI**, Heng, D.Y; “Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC).” ASCO Meeting Abstracts, March 29, 2011. 326.
111. Campbell, S., Knezevic, D., Maddala, T., Novotny, W.F., Zhou, M., Aydin, H., Elson, P.,

- Parodi, L., Goddard, A.D., **Rini, BI**; “Role of quantitative gene expression using RT-PCR in the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC).” ASCO Meeting Abstracts, March 29, 2011:338.
110. **Rini, BI**, Elsen, T., Stenzl, A., Brugger, W., Weinschenk, T., Mahr, A., Fritsche, J., Hilf, N., Mendrzyk, R., Lindner, J., Schmid, A., Kirner, A., Walter, S., Singh, H., Reinhardt, C.; “IMA901 Multipeptide Vaccine Randomized International Phase III Trial: A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC.” ASCO Meeting Abstracts, June 9, 2011: TPS183.
109. Seastone, D.J., Elson, P., Garcia, J.A., Chao, S.T., Suh, J.H., Angelov, L., **Rini, BI**; “Clinical outcome of gamma knife (GK) radiotherapy for central nervous system (CNS) metastases from renal cell carcinoma (RCC).” ASCO Meeting Abstracts, June 9, 2011: e15071.
108. **Rini, BI**, Escudier, B., Tomczak, P., Kaprin, A., Hutson, T.E., Szczylik, C., Tarazi, J.C., Rosbrook, B., Kim, S., Motzer, R.J.; “Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.” ASCO Meeting Abstracts, June 9, 2011:4503.
107. Cella, D., Escudier, B., **Rini, BI**, Chen, C., Bhattacharyya, H., Tarazi, J.C., Rosbrook, B., Kim, S., Motzer, R.J.; “Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).” ASCO Meeting Abstracts, June 9, 2011:4504.
106. Motzer, R.J., de La Motte Rouge, T., Harzstark, A.L., Michaelson, M.D., Liu, G., Gruenwald, V., Ingrosso, A., Tortorici, M.A., Bycott, P.W., Kim, S., **Rini, BI**; “Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial.” ASCO Meeting Abstracts, June 29, 2011:4547.
105. Al-Marrawi, M.Y., **Rini, BI**, Harshman, L.C., Bjarnason, G.A., Wood, L., Vaishampayan, U.N., Mackenzie, M.J., Knox, J.J., Agarwal, N., Kollmannsberger, C.K., Tan, M., Rha, S.Y., Donskov, F., North, S.A., Choueiri, T.K., Heng, D.Y.C.; International mRCC Database Consortium. “The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).” ASCO Meeting Abstracts, June 9, 2011:4555.
104. Heng, D.Y.C., Xie, W., Harshman, L.C., Bjarnason, G.A., Vaishampayan, U.N., Lebert, J., Wood, L., Donskov, F., Tan, M., Rha, S.Y., Wells, C., Wang, Y., Kollmannsberger, C.K., **Rini, BI**, Choueiri, T.K.’ International mRCC Database Consortium. “External validation of the International Metastatic Renal Cell Carcinoma (mRCC) database Consortium prognostic model and comparison to four other models in the era of targeted

- therapy.” ASCO Meeting Abstracts, June 9, 2011:4560.
103. Hutson, T.E., Bukowski, R., **Rini, BI**, Gore, M.E., Larkin, J.M.G., Figlin, R.A., Barrios, C.H., Escudier, B., Lin, X., Fly, K.D., Martell, B., Matczak, E., Motzer, R.J.; “A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (mRCC).” ASCO Meeting Abstracts, June 9, 2011:4604.102.
  102. **Rini, BI**, Elsen, T., Stenzil, A., Brugger, W. Weinschenk, T., Mahr, A., Fritsche, J., Hilf, N., Mendrzyk, R., Lindner, J., Schmid, A., Kirner, A., Walter, S., Singh, H., Reinhardt, C.; “Multi-peptide Vaccine Randomized International Phase III Trial: A randomized, controlled study investigating IMA901 multi-peptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC” J Clinical Onc., Vol 29, issue 15 supp., abstract TPS183.
  101. Chambati, H., Choueiri, T. K., Kollmannsberger, K. K., North, S., Bjarnason, G. A., Vaishampayan, U. N., Wood, L., MacKenzie, M. J., **Rini, BI**, Heng, D. Y.; “Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population 318” Genitourinary Cancers Symposium, 2011.
  100. **Rini, BI**, Szczylik, C., Tannin, N. M., Koralewski, P., Tomczak, P., Deptala, A., Kracht, K., Sun, Y., Puhlmann, M., Escudier, B. “AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer: A randomized, double blind, placebo-controlled, phase II study, 309” Genitourinary Cancers Symposium, 2011.
  99. Sadeghi, S., Albiges, L., Wood, L. S., Black, S. L., Gilligan, T. D., Dreicer, R., Garcia, J. A., Escudier, B. J., **Rini, BI**; “Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and clinical outcome, 307” Genitourinary Cancers Symposium, 2011.
  98. Heng, D.Y., MacKenzie, M. J., Vaishampayan, U. N., Knox, J. J., Bjarnason, G. A., Tan, M. Wood, L., Donskov, B. I., **Rini, BI**, Choueiri, T. K.; “Primary anti-VEGF-refractory metastatic renal cell carcinoma: Clinical characteristics, risk factors, and subsequent therapy, 305” Genitourinary Cancers Symposium, 2011.
  97. Salem, M., Shah, S. N., Wood, L. S., Elson, P., Medsinge, A., Campbell, S., **Rini, BI**. “Contrast enhanced CT changes and nephrometry down-scoring of unresectable primary renal cell carcinoma tumors in patients treated with neoadjuvant sunitinib, 299” Genitourinary Cancers Symposium, 2011.
  96. Peereboom, D., Brewer, C., Suh, J. H., Chao, S. T., **Rini, BI**, Parsons, M., Elson, P., Barnett, G.; “Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with one to three newly diagnosed brain metastases.” J Clin Oncol 28:15s, 2010, abstract TPS148.
  95. Jonasch, E., Bair, A., Chen, Y., **Rini, BI**.” Axitinib with or without dose titration as first-

- line therapy for metastatic renal cell carcinoma (mRCC).” J Clin Oncol 28:15s, 2010, abstract TPS235.
94. Choueiri, T. K., Xie, W., Kollmannsberger, C. K., **Rini, BI.**, McDermott, D. F., Knox, J. J., D., Heng, Y.; “The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration.” J Clin Oncol 28:15s, 2010, abstract 4524.
93. Halabi, S., **Rini, BI.**, Stadler, W. M., Small, E. J.; “Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).” J Clin Oncol 28:15s, 2010, abstract 4525.
92. Kim, J. J., Vaziri, S. A., Elson, P., **Rini, BI.**, Patel, A., Basappa, N. S., Ganapathi, M., Ganapathi, R.; “Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib.” J Clin Oncol 28:15s, 2010, abstract 4629.
91. **Rini, BI.**; “Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC).” Proc Am Soc Clin Oncol 25: abstract 4501, 2010.
90. Heng, D. Y., Xie, W., Bjarnason, G. A., Vaishampayan, U. N., Donskov, F., Wood, L., Knox, J. J., Tan, M., Kollmannsberger, C. K., **Rini, BI.**, Choueiri, T. K.; “A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.” J Clin Oncol 28:15s, 2010, abstract 4523.
89. Trask, P. C., Bushmakina, A. G., Cappelleri, J. C., Tarazi, J. C., Rosbrook, B., Bycott, P. W., Kim, S., Stadler, W. M., **Rini, BI.**; “Can patient-reported kidney cancer-specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma?” J Clin Oncol 28:15s, 2010, abstract 6136.
88. The, B. T., Huang, D., Ding, Y., Zhou, M., **Rini, BI.**, Petillo, D., Qian, C., Kahnoski, R. J., Futreal, P., Furge, K. A.; “The mechanism of action and resistance of sunitinib in RCC.” J Clin Oncol 28, 2010, abstract 13606.
87. **Rini BI,** Kim JJ, Vaziri SA.; “VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients.” Proc Am Soc Clin Oncol 25: abstract 5005. 236s, 2009.
86. **Rini BI,** Schwandt A, Garcia JA.; “A translational phase II trial of celecoxib plus interferon-alpha in metastatic renal cell carcinoma (mRCC) patients with 3 + COX-2 tumor immunostaining.” Proc Am Soc Clin Oncol 25: abstract 5116, 262s, 2009.

85. **Rini BI**, Gordon MS, Stein M.; “Phase I dose escalation trial of tremelimumab plus Sunitinib in patients with metastatic renal cell carcinoma (mRCC).” Proc Am Soc Clin Oncol 25: abstract 5115, 262s, 2009.
84. **Rini BI**, Wood L, Garcia JA.; “Sunitinib in patients with unresectable primary renal cell carcinoma.” Proc Am Soc Clin Oncol 25: abstract 5096, 257s, 2009.
83. Barbastefano J, **Rini BI**, Garcia JA.; “Association of percentage of tumor burden removed with debulking Nephrectomy and progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients treated with VEGF-targeted therapy.” Proc Am Soc Clin Oncol 25: abstract 5095, 257s, 2009.
82. **Rini BI**, Rixe O, Dutcher J.; “Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of Axitinib efficacy in metastatic renal cell carcinoma (mRCC).” Proc Am Soc Clin Oncol 25: abstract 5045, 245s, 2009.
81. **Rini BI**, Elson P, Garcia JA.; “Association of tumor burden characteristics with outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Sunitinib.” Proc Am Soc Clin Oncol 25: abstract 5043, 245s, 2009.
80. Heng DY, **Rini BI**, Xie W.; “Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma, (mRCC) treated with vascular endothelial growth factor (VEGF) targeted agents: Results from a large multi-center study.” Proc Am Soc Clin Oncol 25: abstract 5041, 244s, 2009.
79. Halabi S, **Rini BI**.; “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results in overall survival for CALGB 90206.” Proc Am Soc Clin Oncol 25: abstract LBA5019, 239s, 2009.
78. Bukowski RM, Dreicer R, **Rini BI**.; “Temsirolimus (TEM) in metastatic renal cell carcinoma (mCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy.” Proc Am Soc Clin Oncol abstract 16067, 2008.
77. Heng DY, Elson P, **Rini BI**.; “A retrospective multicenter study of MSKCC poor prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.” Proc Am Soc Clin Oncol abstract 16057, 2008.
76. Vaziri SA, Golshayan AR, **Rini BI**.; “The von Hippel Lindau (VHL) gene status is not always identical in paired primary (P) and metastatic (M) lesion in patients with clear cell renal cell carcinoma (CCRCC).” Proc Am Soc Clin Oncol abstract 16049, 2008.
75. Vakkalanka BK, Elson P, Garcia JA, **Rini BI**.; “Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC).” Proc Am Soc Clin Oncol abstract 16045, 2008.

74. Siddaiah H, Golshayan AR, **Rini BI**.; “Unclassified renal cell carcinoma (RCC): Analysis of clinical and pathologic features.” Proc Am Soc Clin Oncol abstract 16044, 2008.
73. **Rini BI**, Dutcher JP, Wilding GR, Tarazi JC; “Sequential Axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone.” Proc Am Soc Clin Oncol abstract 5127, 2008.
72. Shepard DR, **Rini BI**, Garcia JA; “A multicenter prospective trial of Sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab.” Proc Am Soc Clin Oncol abstract 5123, 2008.
71. George S, Rayman P, **Rini BI**, Elson P.; “Expression of FLT3 and VEGFR1 on myeloid derived suppressor cells (MDSC) in renal cell carcinoma (RCC) patients (pts).” Proc Am Soc Clin Oncol abstract 5108, 2008.
70. Golshayan AR, George S, Heng DY, **Rini BI**.; “Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy.” Proc Am Soc Clin Oncol abstract 5102, 2008.
69. **Rini BI**, Salas RN, Ireland JL.; “Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus.” Proc Am Soc Clin Oncol, abstract 5099, 2008.
68. Faber PW, Vaziri SA, **Rini BI**.; “Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib.” Proc Am Soc Clin Oncol abstract 5009, 2008.
67. **Rini BI**, Schiller JH, Fruehauf JP; “Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736).” Proc Am Soc Clin Oncol abstract 3543, 2008.
66. Cooney MM, Garcia JA, **Rini BI**.; “Sunitinib and bevacizumab in advanced solid tumors: A phase I trial.” Proc Am Soc Clin Oncol abstract 3530, 2008.
65. Rathmell WK, Stadler WM, **Rini BI**.; “Rational therapeutic choices and strategies for patients with metastatic renal cancer.” Proc Am Soc Clin Oncol, 2008.
64. Heng DY, Chi KN, **Rini BI**, Garcia JA, Bukowski RM; “A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer (mRCC).” Genitourinary Cancer Symposium, abstract 395, 2008.

63. Vakkalanka BK, Elson P, Wood L, **Rini BI**, Garica JA; “Long-term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC).” Genitourinary Cancer Symposium, abstract 367, 2008.
62. Golshayan AR, George S, Elson P, **Rini BI**; “VEGF-targeted therapy for metastatic renal cell carcinoma (mRCC) with renal insufficiency.” Genitourinary Cancer Symposiums, abstract 364, 2008.
61. Tamaskar IR, **Rini BI**, Mekhail T, Triozzi P; “A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab for patients (pts) with metastatic renal cell carcinoma (mRCC).” Genitourinary Cancer Symposium, abstract 363, 2008.
60. **Rini BI**, Elson P, Garcia JA, Bukowski RM; “Prospective study of stereotactic radiosurgery (SRS) for pain and tumor control for patients with renal cell carcinoma (RCC) and spinal metastases.” Genitourinary Cancer Symposium, abstract 359, 2008.
59. Elson P, Garcia JA, **Rini BI**; “Dose escalation of Sorafenib in metastatic renal cell carcinoma (mRCC) patients (pts).” Genitourinary Cancer Symposium, abstract 360, 2008.
58. Bukowski RM, Dreicer R, Gilligan T, **Rini BI**; “Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy.” Genitourinary Cancer Symposium, abstract 353, 2008.
57. Garcia JA, Mekhail T, **Rini BI**, Bukowski RM; “Sunitinib and bevacizumab in advanced solid tumors: Preliminary results of a phase I trial.” Genitourinary Cancer Symposium, abstract 352, 2008.
56. **Rini BI**, Halabi S, Rosenberg JE; “CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma.” Genitourinary Cancer Symposium, abstract 350, 2008.
55. Bukowski RM, Garcia JA, **Rini BI**; “Metastatic renal cell carcinoma (mRCC) with sarcomatoid component treated with VEGF-targeted therapy.” Genitourinary Cancer Symposium, abstract 348, 2008.
54. **Rini BI**, Hutson TE, Elson P, Garcia JA; “A prospective trial of Sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab.” Genitourinary Cancers Symposium, abstract 346, 2008.
53. IR Tamaskar, J Unnithan, JA Garcia, R Dreicer, L Wood, A Iochimescu, R Bukowski, **Rini BI**; “Thyroid function test (TFT) abnormalities in patients with metastatic renal cell carcinoma (RCC) treated with sorafenib” 5048 Proc Am Soc Clin Oncol 25: 18S, 2007.
52. JS Unnithan, T Choueiri, J Garcia, R Dreicer, W Laura, R Bukowski, **Rini BI**; “Safety of

- VEGF-targeted tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases” 5047 Proc Am Soc Clin Oncol 25: 18S, 2007.
51. A Golshayan, TK Choueiri, P Elson, JA Garcia, M Kasawneh, S Usman, I Tamaskar L Wood, **Rini BI**; “Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy” 5046 Proc Am Soc Clin Oncol 25: 18S, 2007.
  50. S George, A Richmond, P Elson, T Jin, L Wood, JA Garcia, **Rini BI**, J Finke, RM Bukowski; “WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients receiving Sunitinib” 5043 Proc Am Soc Clin Oncol 25: 18S, 2007.
  49. A Plantade, T Choueiri, B Escudier, **Rini BI**, S Negrier, A Ravaud, S Oudard, P Elson, R Bukowski; “Treatment outcome for metastatic papillary and chromophobe renal cell Carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib” 5037 Proc Am Soc Clin Oncol 25: 18S, 2007.
  48. DJ George, MD Michaelson, JE Rosenberg, RM Bukowski, JA Sosman, WM Stadler, K Margolin, TE Hutson, **Rini BI**; “Phase II trial of sunitinib in Bevacizumab-refractory Metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers” 5035 Proc Am Soc Clin Oncol 25: 18S, 2007.
  47. **Rini BI**, GT Wilding, G Hudes, WM Stadler, S Kim, JC Tarazi, PW Bycott, KF Liao, JP Dutcher; “Axitinib (AG-013736: AG) in patients with metastatic renal cell cancer (RCC) refractory to sorafenib” 5032 Proc Am Soc Clin Oncol 25: 18S, 2007.
  46. TK Choueiri, SA Vaziri, **Rini BI**, P Elson, I Bhalla, E Jaeger, V Weinberg, FM Waldman M Zhou, RM Bukowski, R Ganapathi; “Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) targeted therapy in metastatic renal cell carcinoma (RCC).” 5012 Proc Am Soc Clin Oncol 25: 18S, 2007.
  45. ME Gore, C Porta, S Oudard, G. Bjarnason, D. Castellano, C. Szczylik, PN Mainwaring, P Schoffski, **Rini BI**, RM Bukowski; “Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis” 5010 Proc Am Soc Clin Oncol 25: 18S, 2007.
  44. L Fong, B Kavanagh, Y Hou, S O’Brien, J Valiente, V Weinberg, **Rini BI**, EJ Small; “Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells.” 3001 Proc Am Soc Clin Oncol 25:18S, 2007.
  43. **Rini BI**, George DI, Michaelson MD, et al: “Phase II of Sunitinib Malate (SU11248) in



- bevacizumab-refractory Metastatic Renal Cell Carcinoma.” Proc Am Soc Clin Oncol 17(9s), 2006.
42. Shaheen PE, Tamaskar IR, Salas RN, **Rini BI**, Garcia J, Wood L, Dreicer R, Bukowski RM; “Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with bevacizumab.” 4605 Proc Am Soc Clin Oncol 24:18S, 2006.
  41. Al Hazzouri A, Vaziri SA, Lynch M, Schwartz B, **Rini BI**, Bukowski RM, Ganapathy R; “Anti-proliferative effects of bevacizumab in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia.” 4601 Proc Am Soc Clin Oncol 24:18S, 2006.
  40. Tamaskar I, Shaheen P, Wood L, Hodnick S, Nemec C, Garcia J, Dreicer R, **Rini BI**, Bukowski RM; “Antitumor effects of bevacizumab and bevacizumab in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents.” 4597 Proc Am Soc Clin Oncol 24:18S, 2006.
  39. Choueiri TK, Dreicer R, **Rini BI**, Elson P, Garcia J, Mekhail T, Bukowski RM; “Phase II Study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (mRCC)” 4539 Proc Am Soc Clin Oncol 24:18S, 2006.
  38. Houk EB, Amantea M, Motzer RJ, Michaelson MD, **Rini BI**, George DJ, Redman BG, Hudes GR, Poland B, Bello CL; “Pharmacokinetics (PK) and efficacy of bevacizumab in patients with metastatic renal cell carcinoma (mRCC).” 4531 Proc Am Soc Clin Oncol 24:18S, 2006.
  37. **Rini BI**, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Margolin K, Hutson TE, Baum CM; “Efficacy and safety of bevacizumab malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).” 4522 Proc Am Soc Clin Oncol 24:18S, 2006.
  36. Suppiah R, Finke J, **Rini BI**, Richmond A, Wood L, Elson P, Shaheen P, Garcia J, Dreicer R, Bukowski R; “T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during bevacizumab treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias.” 2526 Proc Am Soc Clin Oncol 24:18S, 2006.
  35. Fong L, Kavanaugh B, **Rini BI**, Shaw V, Weinberg V, Small EJ; “A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer.” 2508 Proc Am Soc Clin Oncol 24:18S, 2006.
  34. **Rini BI**, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, et al. “AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase II study of cytokine-refractory, metastatic renal cell cancer.” Proc Am Soc Clin

Oncol 23:380, 2005.

33. Lin AM, Ryan CJ, Rosenberg J, **Rini BI**, Nguyen T, Weinberg VI, Small EJ. "A phase II trial of ketoconazole plus granulocyte/macrophage colony stimulating factor (GM-CSF) in androgen-independent prostate cancer patients." Proc Am Soc Clin Oncol 23:406, 2005.
32. Beaumont J, Cella D, Li J, Motzer R, **Rini BI**, et al. "Patient reported outcomes in a phase II trial of SU11248 for metastatic renal cell carcinoma." Proc Am Soc Clin Oncol 23:770, 2005.
31. Motzer RJ, **Rini BI**, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. "Phase II trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma." Proc Am Soc Clin Oncol 23:380, 2005
30. **Rini BI**, Weinberg V, Fong L, Small EJ. "A phase 2 study of prostatic acid phosphatase-pulsed dendrite cells (APC8015) in combination with bevacizumab in patients with serologic progression of prostate cancer after local therapy." Proc Multidisciplinary Prostate Cancer Symposium, abstract 251, 2005.
29. **Rini BI**, Weinberg V, Fong L, Small EJ. "Clinical and immunologic characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with GM-CSF." Proc Multidisciplinary Prostate Cancer Symposium, abstract 261, 2005.
28. Ryan CJ, Rosenberg J, **Rini BI**, Nguyen T, Weinberg V, Small E.; "A phase II trial of ketoconazole plus granulocyte macrophage colony stimulating factor (GM-CSF) in androgen independent prostate cancer." Proc Multidisciplinary Prostate Cancer Symposium, abstract 296, 2005.
27. Lin AM, Fong K, Weinberg V, **Rini BI**, Ryan CJ, Rosenberg J, Fong L, Haqq C, Small EJ; "A phase II trial of imatinib mesylate in prostate cancer patients with biochemical relapse after definitive local therapy." Proc Multidisciplinary Prostate Cancer Symposium, abstract 258, 2005.
26. S.E. DePrimo, Bello, C.L., Smeraglia, J., Shalinsky, D.R. Freddo, J., Baum, C.M. **Rini**, B.I, Michaelson, M.D., Motzer, R.J., Spinella, D.; "Soluble Protein Biomarkers of Pharmacodynamic Activity of the Multi-Targeted Kinase Inhibitor SU011248 in Patients with Metastatic Renal Cell Cancer." AACR, 2005.
25. **Rini BI**, Beinart G, Small EJ, Verjee S, and Hershberg RM.; "Immunotherapy (APC8015) for Androgen Dependent, Biochemically-Relapsed Prostate Cancer." AUA 2005.
24. Eisenberg MS, Stoller MS, Master VA, Meng MV, **Rini BI**, Carroll PR, Kane CJ.; "Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal Cell

Carcinoma.” AUA, 2005.

23. **Rini BI**, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, McCarthy PL; “Linker CA and Small EJ. CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.” *Blood*, 104 (11), 2004 (abstract #810).
22. **Rini BI**, Weinberg V, Cadman B, Elchinoff A, Yu N, Bok R, Small E.; “A phase II trial of interferon-alpha and celecoxib in metastatic renal cell carcinoma: Clinical and anti-angiogenic effects.” *Proc Am Soc Clin Oncol* 23: 406, 2004.
21. Motzer RJ, **Rini BI**, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. “SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.” *Proc Am Soc Clin Oncol* 23: 381, 2004.
20. Fong L, **Rini BI**, Kavanaugh B, Small E.; “CTLA-4 blockade-based immunotherapy for prostate cancer.” *Proc Am Soc Clin Oncol* 23: 185, 2004.
19. Garcia JA, Weinberg V, **Rini BI**, Rosenberg JE, Ryan CJ, Small EJ.; “Prior estrogen therapy as a predictor of response to subsequent estramustine-based therapy in androgen-independent prostate cancer patients.” *Proc Am Soc Clin Oncol* 23: 404, 2004.
18. Randall M, **Rini BI**, Ryan C, Rosenberg J, Garcia J, Bublely G, Small EJ; “The addition of imatinib mesylate to estramustine/docetaxel for the treatment of hormone refractory prostate cancer patients: Results of a phase I trial.” *Proc Am Soc Clin Oncol* 23: 409, 2004.
17. **Rini BI**, Weinberg V, Bok RA, Nguyen S, Small EJ; “A phase II study of prostatic acid phosphatase-pulsed dendritic cells (APC8015; Provenge) in combination with bevacizumab in patients with serologic progression of prostate cancer after local therapy.” *Proc Am Soc Clin Oncol* 22: 174, 2003.
16. Stadler WM, Rosner G, **Rini BI**, Hollis D, Small E, Ratain M.; “Successful implementation of the randomized discontinuation trial design with the putative antiangiogenic agent carboxyaminoimidazole (CAI) in renal cell carcinoma. A Cancer and Leukemia Group B (CALGB) Study.” *Proc Am Soc Clin Oncol* 22: 193, 2003.
15. Small EJ, **Rini BI**, Higano C, Redfern C, Nemunaitis J, Valone F, Kylstra J, Schellhammer P.; “A randomized placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer.” *Proc Am Soc Clin Oncol* 22: 382, 2003.
14. Kelly WK, Galsky MD, Small E, **Rini BI**, Oh W, Kantoff, P, Chen I, Davar U, Delacruz A, Scher H.; “Multi-institutional trial of epothilone B analogue with or without

- estramustine phosphate in patients with progressive castrate-metastatic prostate cancer.” Proc Am Soc Clin Oncol 22: 394, 2003.
13. Smith M, Kaufman D, George D, Oh W, Slovin S, **Rini BI**, Small E, Kazanis M, Manola J, Kantoff P.; “Rosiglitazone versus placebo for men with prostate cancer and a rising PSA after radical prostatectomy and/or radiation therapy.” Proc Am Soc Clin Oncol 22: 395, 2003.
  12. Shaw VA, **Rini BI**, Park JW, Small EJ; “A phase II study of UCN-01 in advanced renal cell carcinoma.” Proc Am Soc Clin Oncol 22: 442, 2003.
  11. Small EJ, Kantoff PW, Weinberg V, Nguyen S, Smith M, Bublely G, **Rini BI**, Bok R, Kakefuda M, Haqq C, Oh WK.; “A Prospective Multicenter Randomized Trial of the Herbal Supplement, PC-SPEs vs. diethylstilbestrol (DES) in Patients with Advanced, Androgen Independent Prostate Cancer (AiPCa.)” Proc Am Soc Clin Oncol 21:178a, 2002 (abstr 709).
  10. Hu HS, **Rini BI**, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ.; “Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer After Non-Myeloablative Chemotherapy: Updated Results.” Proc Am Soc Clin Oncol 21:180a, 2002 (abstr 718).
  9. George CM, Huo D, Vogelzang NJ, **Rini BI**, Ryan CW, Desai AA, Stadler WM.; “Pooled Analysis of Advanced Renal Cell Carcinoma (RCC) Patients (Pts) Treated with Gemcitabine (G) and 5-Fluorouracil (F).” Proc Am Soc Clin Oncol 21:191a, 2002 (abstr 762).
  8. **Rini BI**, Zimmerman TM, Gajewski TG, Stadler WM and Vogelzang NJ; “Allogeneic Stem Cell Transplantation of Metastatic Renal Cell Cancer After Non-myeloablative Chemotherapy: Engraftment Rates, Toxicity and Initial Clinical Results.” Proc Am Soc Clin Oncol 20:180a, 2001 (abstr 719).
  7. Rodriguez M, George CM, Vogelzang NJ, **Rini BI**, Stadler WM; “A Phase II Trial of Weekly Intravenous Gemcitabine and Cisplatin with Prolonged Continuous Infusion 5-Fluorouracil in Patients with Metastatic Renal Cell Carcinoma.” Proc Am Soc Clin Oncol 20:175b, 2001 (abstr 2450).
  6. Desai A, Vogelzang NJ, **Rini BI**, Ryan C, Rodriguez M, Stadler WM; “A Phase II Trial of Weekly Intravenous Gemcitabine (G) with Prolonged Continuous Infusion 5-Fluorouracil (F) and Oral Thalidomide (T) in Patients with Metastatic Renal Cell Cancer (mRCC).” Proc Am Soc Clin Oncol 20:174b, 2001 (abstr 2448).
  5. Gajewski TF, Flickinger SF, Heimann R, Karczmar G, **Rini BI**, Dragovich T, Stadler WM; “Phase II Study of the Anti-Angiogenic Flk-1 Tyrosine Kinase Inhibitor SU5416 in Melanoma: Initial Results.” Proc Am Soc Clin Oncol 20, 2001 (abstr 1436).

4. **Rini BI**, Gavin D, Vogelzang NJ, Bosman J, Pantail A, Gajewski TF, Stadler WM; “Circulating Dendritic Cells In Vivo After Sequential Administration of Flt-3 Ligand and Interleukin-2 in Metastatic Renal Carcinoma Patients.” *Blood* 96(11): 455a, 2000 (abstr 1960).
3. **Rini BI**, Stadler WM, Smith S, Bosman J, Gavin D, Vogelzang NJ, Gajewski TF; “Characterization of Circulating Dendritic Cells (DC) in Metastatic Renal Carcinoma (RC) Patients (Pts) Following FLT-3 Ligand (Flt-3L) Treatment with or without Interleukin-2.” *Proc Am Soc Clin Oncol* 19:361a, 2000 (abstr 1424).
2. **Rini BI**, Ryan CW, Vogelzang NJ, Stadler WM; “A Phase II Trial of Weekly Intravenous Gemcitabine with Continuous Infusion 5-Fluorouracil (5-FU) in Patients with Metastatic Renal Cell Cancer.” *The First International Kidney Cancer Symposium*. October, 1999.
1. **Rini BI**, Stadler WM, Danet G, Smith S; “Characterization of Dendritic Cell Subsets Stimulated by Flt-3 Ligand Administration in Renal Carcinoma Patients.” *Annual Meeting of the Central Society for Clinical Research*. September, 1999.

## SELECTED SEMINARS AND INVITED LECTURESHIPS

### Local/Regional

UCSF Medicine Grand Rounds, <i>Renal Cell Carcinoma: 2002 Update</i>	2002
American College of Surgeons Chapter meeting presentation: <i>Advances In the Treatment of Hormone-Refractory Prostate Cancer</i>	2002
UCSF Advances in Internal Medicine, <i>Advances in the Treatment of Hormone-Refractory Prostate Cancer</i>	2002
Association of Northern California Oncologists: <i>Genitourinary ASCO Highlights</i>	2002
Kidney Cancer Association Survivor's Day, <i>Non-myeloablative Allogeneic Transplantation for Metastatic Renal Carcinoma</i>	2002
UCSF Medicine Grand Rounds: <i>Renal Cell Carcinoma: 2002 Update</i>	2002
American College of Surgeons Chapter meeting presentation, <i>Advances In the Treatment of Hormone-Refractory Prostate Cancer</i>	2002
UCSF Urology Seminar, <i>High-dose Casodex in Prostate Cancer, Novel Treatments for Renal Carcinoma, Secondary Hormones for Prostate Cancer, Bladder Cancer – Advanced Disease Options &amp; Early Stage Germ Cell Tumors</i>	2003
Seton Medical Center Grand Rounds, <i>Bisphosphonates in Prostate Cancer</i>	2003
UCSF Department of Radiology Grand Rounds, <i>Inhibiting the VEGF Pathway in Renal Carcinoma</i>	2004
UCSF Department of Urology Grand Rounds, <i>VEGF-targeted Therapy In Metastatic Renal Carcinoma</i>	2005
CCF Annual Multidisciplinary Genitourinary Oncology Course	2005 - present
CCF Taussig Cancer Center Grand Rounds, <i>Rational Selection of New Agents for RCC</i>	2005
CCF Fellows Lecture Series: <i>Kidney cancer</i>	2005 - present
Kidney Cancer Association 2 <sup>nd</sup> International Symposium, <i>Non-Myeloablative Allogeneic Transplantation for Metastatic Renal Carcinoma</i>	2001
Second International Symposium on GU Cancers, <i>Prostate Cancer Immunotherapy</i>	2002

Second International Congress on Targeted Therapies in Cancer, <i>Inhibiting the VEGF Pathway in Renal Carcinoma</i>	2003
Baylor College of Medicine GU Grand Rounds, <i>Inhibiting the VEGF Pathway in Renal Carcinoma</i>	2003
Third International Symposium on GU Cancers, <i>Prostate Cancer Immunotherapy</i>	2004
ASCO 2004 Annual Meeting Special Session, CALGB 90206, <i>High-Priority Cooperative Group Phase III Trials for Community Practitioners</i>	2004
ASCO Satellite Symposium, <i>Targeting Growth and Angiogenic Pathways: From Bench to Bedside. Angiogenic Inhibitors in Advanced Kidney Cancer</i>	2004
SPORE National Meeting, <i>GM-CSF Plus CTLA-4 Blockade for Prostate Cancer</i>	2004
NCI Meeting, <i>New Treatment Options for Renal Cell Carcinoma, Clinical Development of Novel Therapy for Metastatic Renal Carcinoma</i>	2004
Kidney Cancer Association 3 <sup>rd</sup> International symposium, <i>CALGB90206: Interferon +/- Avastin in Metastatic RCC</i>	2004
American Society of Hematology CALGB 90003, Invited Speaker, <i>Non-myeloablative Transplantation for Metastatic Renal Carcinoma</i>	2004
National Comprehensive Cancer Network Annual Investigator's Meeting, <i>Celecoxib Plus Interferon Alpha for Metastatic Renal Carcinoma</i>	2004
4 <sup>th</sup> International Symposium on Genitourinary Cancers: Organizing Committee; Lectures: <i>Summary of VEGF-targeted Therapy in Metastatic RCC, Incorporation of VEGG-targeted Therapy with Cytokines in Metastatic RCC, Prostate Cancer Immunotherapy and Clinical Trials in Rising PSA Patients</i>	2005
UCSF Department of Urology Seminar, <i>Maximizing Outcomes in Urologic Oncology, Metastatic Renal Carcinoma</i>	2005
ASCO Prostate Cancer Symposium, <i>Prostate Cancer Immunotherapy</i>	2005
2 <sup>nd</sup> International Congress on Kidney and Bladder Cancer, <i>AG013736 in Renal Cell Carcinoma</i>	2005
NCI Kidney Cancer: New Therapeutic Options Investigators Conference: <i>Anti-Angiogenic Agents: Phase II and III Data – AG013736</i>	2005
University of North Carolina Grand Rounds, <i>Molecular Targeting in Metastatic Renal Cell Carcinoma</i>	2005

Current Trends in Kidney, Bladder and Prostate Cancer, <i>Recent Advances in Understanding the Pathogenesis of Kidney Cancer and Sunitinib: Role of a Multikinase Inhibitor</i>	2005
8 <sup>th</sup> International Symposium on Anti-Angiogenic Agents, <i>Renal Cell Carcinoma</i>	2006
Emory Cancer Institute Annual Hematology/Oncology Review, <i>Novel Therapies for Renal Cell Carcinoma</i>	2006
3 <sup>rd</sup> International Congress on Kidney and Bladder Cancer, Moderator, <i>Novel Targeted Approaches: Renal Cell Carcinoma</i>	2006
2 <sup>nd</sup> Innovation and Challenges in RCC Conference, Invited Speaker	2006
Delaware Society of Clinical Oncology: Invited Speaker, <i>Renal Cell Carcinoma</i>	2006
Harvard Medical School, Brigham & Women's Hospital GU Review Course: Invited Speaker, <i>Hormone Treatment in Advanced Prostate Cancer; Renal Cell Carcinoma</i>	2006
2 <sup>nd</sup> Annual Oncology Congress: <i>Controversies in Genitourinary Oncology – Renal Cell Carcinoma: What is Standard Therapy?</i>	2006
3 <sup>rd</sup> International Symposium on Angiogenesis in Cancer: <i>Sunitinib; Axitinib updates</i>	2006
Society of Urologic Oncology Annual Meeting: Steering Committee Member; Invited Speaker, <i>Targeted Therapy in Renal Cell Carcinoma</i>	2006
American Society of Hematology (ASH) Annual Meeting: ASH/ASCO Joint Symposium: <i>Anti-angiogenic Therapy in RCC and Other Solid Tumors</i>	2006
9 <sup>th</sup> International Symposium on Anti-Angiogenic Agents: <i>Targeted Anti-Angiogenic Therapy for Advanced Renal Cell Carcinoma</i>	2007
6 <sup>th</sup> International Kidney Cancer Symposium: <i>What is the Definition of Targeted Therapy Failure?</i>	2007
International Society for Biologic Therapy (ISBT): Moderator, New Agents session, Invited Speaker, <i>Targeted Therapy for Advanced Renal Cell Carcinoma</i>	2007
Society of Urologic Oncology Annual Meeting: Steering Committee Member; Invited Speaker, <i>Management of Metastatic Disease</i>	2007
Genitourinary Cancer Symposium 2008: <i>Interpreting and Applying an Evolving Standard of Care in Advanced Renal Cell Carcinoma: Individualizing Patient Care</i>	2008



Genitourinary Cancer Symposium, Oral Presentation: <i>CALGB 90206: A Phase III Trial of Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Metastatic Renal Cell Carcinoma</i>	2008
American Urological Association (AUA) Annual Meeting Course: <i>Kidney Cancer: Advances in the Management of SRM's and Advanced Disease</i>	2008
ASCO 2008 Annual Meeting: <i>RCC Educational Session</i>	2008
3 <sup>rd</sup> Innovation and Challenges in RCC Conference: Invited Speaker: <i>VEGF-targeted Therapy</i>	2008
18 <sup>th</sup> Annual Hematology/Oncology Multidisciplinary Reviews (Mayo Clinic) <i>Distinguished Guest Faculty</i>	2008
7 <sup>th</sup> International Kidney Cancer Symposium: Steering Committee Member; Invited Speaker, <i>Making a Case for Initial Observation/Clinical Trial</i>	2008
ASCO-NCI-EORTC Annual Meeting: Invited Speaker, <i>Molecular Markers of Response &amp; Resistance to VEGFR Inhibitors in RCC</i>	2008
Society of Urologic Oncology Meeting, Steering Committee Member/Moderator, <i>RCC session</i>	2008
Fourth Annual Community Oncology Conference, Invited Speaker	2009
ASCO Genitourinary Cancer Symposium, Invited Speaker: <i>Pre-surgical Targeted Therapy in RCC; RCC Journal Club speaker</i>	2009
Clinical Care Options: <i>Master Class on Evolving Evidence &amp; Emerging Treatments: Targeted Agents in Advanced RCC</i>	2009
3 <sup>rd</sup> Annual Perspectives in Genitourinary Oncology: Panel Member: <i>Management of Advanced Prostate Cancer; Renal Cancer; Management of Advanced Renal Cancer</i>	2009
Dartmouth-Hitchcock Medical Center Grand Rounds: <i>Individualized Therapy for Metastatic Renal Cell Carcinoma</i>	2009
8 <sup>th</sup> International Kidney Cancer Symposium, Planning Committee; Moderator: <i>Emerging Applications of Established VEGF and mTOR Therapy for mRCC</i>	2009
12 <sup>th</sup> Annual Symposium on Anti-Angiogenic Agents, Invited Speaker, <i>Hypertension as a biomarker of efficacy in patients with mRCC treated with Sunitinib</i>	2010
UCLA Genitourinary GU Lecture Series: <i>Predictive Biomarkers for Targeted</i>	2010

*Therapy in Metastatic Renal Carcinoma*

Genitourinary Cancers Symposium; Oral presentations 1) <i>Hypertension as a biomarker of clinical outcome with sunitinib in metastatic RCC</i> and 2) <i>Sunitinib Re-challenge in metastatic RCC</i>	2010
Karmanos Cancer Institute Grand Rounds, Invited Speaker	2010
ASCO Annual Meeting, Invited Speaker, <i>Identification of Prognostic Genomic Markers in Patients with Localized Clear Cell Renal Cell Carcinoma</i>	2010
MDACC Comprehensive Board Review in Hematology and Medical Oncology; Invited Speaker, <i>Renal Cell Carcinoma</i>	2010
Ninth International Kidney Cancer Symposium – Invited speaker and Expert Panelist; <i>Switching to mTOR Inhibition vs. Maintaining VEGF Inhibition After VEGF Therapy Failure</i>	2010
Mary Babb Randolph Cancer Center, University of West Virginia; - Invited Speaker; <i>Renal Cell Carcinoma</i>	2010
Society of Urologic Oncology 2011 Winter Meeting, Bethesda, Maryland – Invited Speaker, <i>Renal Cell Carcinoma</i>	2010
Lilly Oncology Conference, Indianapolis, Indiana – Invited Speaker, <i>Renal Cell Carcinoma</i>	2010
13 <sup>th</sup> Annual Symposium on Anti-Angiogenic Agents, Invited Speaker, <i>Anti-Angiogenic Therapy for RCC</i> , Panelist	2011
2011 Genitourinary Cancers Symposium. Invited Speaker, <i>AMG386 Alone or in Combination with Sorafenib: Results of a Randomized Phase II Trial.</i>	2011
ASCO GU Annual Meeting, Chairperson, <i>Multidisciplinary Assessments in Advanced Renal Cell Carcinoma: Translating Evidence Into Practice</i>	2011
American Association for Cancer Research 102 <sup>nd</sup> Annual Meeting, Chairperson, Invited Speaker, <i>Clinical Applications of Genomic Classification of RCC</i>	2011
14 <sup>th</sup> Annual Moll Pavilion Cancer Symposium, Invited Speaker, <i>Kidney Cancer: New Advances in Treatment</i>	2011
Kidney Cancer Association, Invited Speaker, <i>Molecular Insights in Renal Cell Carcinoma</i> , Chicago, Illinois	2011
Chemotherapy Foundation Meeting, Invited Speaker, <i>Axitinib in RCC</i> , New York, New York	2011

Keystone Symposium on Molecular and Cellular Biology, Invited Speaker, <i>Antio-Angiogenic Therapy in the Clinic: Where We Are, Where We Are Going and How We Will Get There</i> , Snowbird, Utah	2012
2012 Genitourinary Cancers Symposium, Invited Speaker, <i>Renal Cell Carcinoma</i> , San Francisco, California	2012
14 <sup>th</sup> International Symposium on Anti-Angiogenic Therapy, Invited Speaker, <i>Renal Cell Carcinoma</i> , San Diego, California	2012
Mercy Cancer Center, Invited Speaker, <i>Individualized Treatment for Patients with Renal Cell Carcinoma: Bridging the Gap between Evidence and Clinical Practice</i> , Canton, Ohio	2012
<i>Tumor Microenvironment: Focus on the Target</i> , Invited Speaker, Society for Immunotherapy of Cancer, North Bethesda, Maryland	2012
Dana Farber Cancer Institute, Invited Speaker 16 <sup>th</sup> Biennial Urologic Cancer Course , Boston, Massachusetts	2012
<i>The Case for Moving Axitinib into the Front Line</i> , Invited Speaker, Kidney Cancer Association, Chicago, Illinois	2012
<i>Renal Cell Carcinoma in 2012 and Beyond: An Expert Roundtable Discussion</i> , Invited Speaker, TRM Oncology, Elizabeth, New Jersey	2012
<i>Maintaining Dose Intensity and Best Supportive Care: How Important is Dose Intensity and When is Dose Reduction the Better Strategy?</i> , Invited Speaker, Genitourinary Cancer Symposium, Orlando, Florida	2013
Grand Rounds, Invited Speaker, University of Cincinnati Hematology/Oncology, Cincinnati, Ohio	2013
Regional Cancer Center Cancer conference, Seven Spring, PA	2014
The New York Academy of Sciences: Angiogenesis in RCC, New York, NY	2014
Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow NY, NY Limiting Treatment Related Morbidity in RCC; Observation and intermittent Rx	2014
Accelerating Anticancer Agent Development & Validation Workshop Bethesda, MD	2015
FDA Renal Cell Carcinoma Symposium Silver Spring, MD	2015

## SELECTED SEMINARS AND INVITED LECTURESHIPS

### International

Avastin Finnish Launch Symposium: <i>Avastin in the Treatment of Renal Carcinoma</i> ; Helsinki, Finland	2005
Brazilian Congress of Clinical Oncology Satellite Symposium: <i>SU11248 in Renal Cell Carcinoma</i> , Rio de Janeiro, Brazil	2005
31 <sup>st</sup> European Society for Medical Oncology (ESMO) Meeting: Invited oral presentation: <i>Phase II Study of Sunitinib Malate (SU11248) in Bevacizumab-refractory Metastatic Renal Cell Carcinoma</i> ; Istanbul, Turkey	2006
5 <sup>th</sup> International Symposium on Targeted Anticancer Therapies: <i>Treatment of Advanced Renal Carcinoma</i> ; Amsterdam, the Netherlands	2007
14 <sup>th</sup> European Cancer Conference (ECCO): Invited oral presentation: <i>A Phase II Trial of Axitinib in Sorafenib-refractory RCC</i> ; Barcelona, Spain	2007
7 <sup>th</sup> World Basic Urological Research Congress: Moderator RCC session; Lecture: <i>Targeted Therapy for Advanced RCC</i> ; Dublin, Ireland	2007
New Zealand Urological Society: Video Presentation <i>Targeted Therapy for Advanced Renal Cell Carcinoma</i> ; New Zealand	2007
Japan Urological Association Annual Meeting: Invited lecture: <i>Optimal Therapy for Metastatic RCC</i> ; Yokohama, Japan	2008
Renal Cell Carcinoma Summit: Invited Speaker: <i>TKI International Authority Panel on RCC</i> ; Barcelona and Madrid, Spain	2008
2 <sup>nd</sup> Canadian Kidney Cancer Forum, <i>Invited Speaker</i>	2009
7 <sup>th</sup> Annual Hematology Oncology Targeted Therapies (HOTT) Symposium: <i>Keynote Speaker</i> , Sydney & Melbourne Australia	2009
2 <sup>nd</sup> Pavia International Symposium on Advanced Kidney Cancer, Invited Speaker: <i>Treatment Algorithm for Advanced Kidney Cancer</i> , Pavia, Italy	2009
4 <sup>th</sup> Annual Latin America Oncology Forum: Chairman; Santiago, Chile	2009
Portugal GPGU Meeting, Invited Speaker, <i>Castrate-resistant Prostate Cancer Treatment Options and Novel Treatment Options in Metastatic RCC</i> , Porto, Portugal	2010
4 <sup>th</sup> Post-ASCO Meeting on Advanced Kidney Cancer, Invited Speaker, <i>What's New Behind the Corner? New Treatment Options in the Arena – Axitinib</i> , Arezzo, Italy	2010

European Kidney Cancer Association Meeting, Invited Speaker, <i>Neoadjuvant Therapy for Poor-risk RCC</i> , London, England	2010
Scientific Meeting SOGUG, Invited Speaker, <i>Beyond the First Line; the Role of New TKI</i> . Madrid Spain	2010
Invited Speaker, <i>New Choices in Advanced Renal Cell Carcinoma</i> , London, England; Dublin, Ireland	2011
Asian Oncology Summit 2011, Genitourinary Cancer Summit Lecture, Invited Speaker, Renal Cell Carcinoma, Hong Kong and Beijing, China	2011
Sixth European International Kidney Cancer Symposium, Invited Speaker, <i>Genetic and Genomic</i> , Warsaw, Poland	2011
Educational Cancer Convention Lugano (ECCLU), Invited Speaker, <i>Kidney Cancer: First and Further Lines in mRCC</i> , Lugano, Switzerland,	2011
University of Toronto Grand Rounds, Invited Speaker, <i>New Directions in the Treatment of Advanced RCC</i> , Toronto, Canada	2011
Latin American Clinical Oncology Research Group (GLICO) Invited Speaker, Rio de Janeiro, Brazil	2011
European Society for Medical Oncology (EMSO 2012) Oral Presentation, Vienna, Austria	
London Cancer Center invited speaker London, England	2014
V International Congress of Uro-Oncology Sao Paulo, Brazil	2014
Kidney Cancer Association Dublin, Ireland	2014
Visiting Speakers Program in Oncology Montreal, Canada	2014
Vall d'Hebron University Hospital Barcelona, Spain	2014
Russian Society of Clinical Oncology Moscow, Russia	2015
Invited Lecturer, Israel Society of Oncology and Radiation Therapy	2015
ANZUP Annual Meeting speaker Sydney, Australia	2015
VI IAOC Conference "Current Status and Future of Anti-Cancer Targeted Therapies Buenos Aires, Argentina	2015

**PEER-REVIEWED RESEARCH SUPPORT**

**Ongoing**

**5P30 CA043703-27 (Gerson, PI)** 08/01/97-03/31/18 7%  
 effort  
 NIH/NCI  
 Comprehensive Cancer Center Support Grant

The objectives of the Center are to: 1) improve the prevention, diagnosis, and therapy of cancer through research; 2) stimulate and support innovative, coordinated, interdisciplinary research on cancer diagnosis, treatment, and control; 3) develop clinical applications of research discoveries and to make these applications available as quickly as possible; and 4) develop cancer prevention and control activities to contribute to the reduction of cancer morbidity and mortality in NE Ohio and the surrounding region and nation.

Role: Leader, GU Malignancies Program

**1 R01 CA168488-05 (Finke, PI)** 02/01/13-01/31/18 3%  
 effort  
 NIH/NCI  
 Regulation of MDSC Function and Trafficking

The production of inflammatory proteins by tumors enhances the accumulation of myeloid derived suppressor cells (MDSC), a group of immature white blood cells that promote tumor progression by suppressing tumor immunity and enhancing blood vessel formation. Inflammatory tumors promote the development of these cell populations and enhance their immune suppressive and tumor promoting functions. We have found that the tumor promoting activity is enriched in select subsets of MDSC particularly those expressing the chemokine receptor CXCR2 and that these subsets are attracted to the tumor site by inflammatory products. Understanding the individual contributions of inflammatory proteins and their impact in promoting the activation and migration of these highly active MDSC subsets (CXCR2+) may lead to new targets for therapeutic intervention

Role: Co-Investigator

**Completed**

5R21 CA123854-03	NIH/NCI	Therapeutic Modulation of COX-2-Induced Immunosuppression in Metastatic Renal Cell Carcinoma	Principal Investigator	4/07- 3/10	\$200,000
W81XWH-04-1-0127	Department of Defense New Investigator Award	CTLA-4 Blockade Based Immunotherapy in Prostate Cancer	Principal Investigator	1/04 – 1/07	\$225,000
RPC 2005-1092	CCF Research Programs Council	Immunoregulatory Effects of Cyclooxygenase-2 (COX-2) Expression in Renal Cell Carcinoma	Principal Investigator	1/06– 1/08	\$50,000

5R33CA1230 27-04	NIH/NCI	Integrated Microdevice to Capture and Detect Circulating Tumor Cells	Co- Investigator	09/08-8/12	\$84,536
5R01CA1290 34-05	NIH/NCI	Predictive Markers in Metastatic Renal Cancer	Co- Investigator	07/08-05/14	\$19,726
5U01CA0625 02-16	NIH/NCI	DNA Metabolizing Enzyme Targeted Therapy/Phase I Trials of Anti-Cancer Agents	Co- Investigator	03/94-03/15	\$102,327

## TEACHING ACTIVITIES - MENTORSHIP/PRECEPTORSHIP

<u>Name</u>	<u>Years Mentored</u>	<u>Current Position</u>	<u>Significant Attributable Accomplishments</u>
<b>Hematology / Oncology Fellows</b>			
Toni Choueiri	2005-2008	Faculty, Harvard / Dana Farber Cancer Center	<ul style="list-style-type: none"> <li>• 6 publications (<i>JCO, Cancer</i>)</li> <li>• ASCO oral presentation</li> </ul>
Jenny Kim	2006-2009	Faculty, Johns Hopkins	<ul style="list-style-type: none"> <li>• ASCO oral presentation</li> <li>• Vail workshop participant</li> </ul>
Sarmad Sadeghi	2010-2011	UCLA	<ul style="list-style-type: none"> <li>• Vail workshop participant</li> <li>• ASCO GU oral presentation</li> </ul>
Kritti Mittal	2011 - 2014	Private Practice	<ul style="list-style-type: none"> <li>• KCA oral presentation</li> <li>• Vail workshop participant</li> <li>• ASCO Merit Award</li> </ul>
Moshe Ornstein	2014-2017	CCF Faculty	<ul style="list-style-type: none"> <li>• JCO publication, ASCO GU presentation</li> <li>• Vail workshop participant</li> </ul>
Vadim Koshkin	2015 - 2018	USCF Faculty	<ul style="list-style-type: none"> <li>• Vail workshop participant</li> </ul>
Haris Zahoor	2015 - 2018	USC Faculty	<ul style="list-style-type: none"> <li>• Vail workshop participant</li> </ul>
Jaleh Fallah	2018 - present	CCF Fellow	<ul style="list-style-type: none"> <li>• Vail workshop participant</li> </ul>
<b>Experimental Therapeutics Fellowship</b>			
Daniel Heng	2007-2008	Assistant Professor, University of Calgary	<ul style="list-style-type: none"> <li>• 2 publications</li> <li>• ASCO, ASCO GU presentations</li> </ul>
Bhanu Vakkalanka	2007-2008	Hematology/Oncology Fellow, University of Iowa	<ul style="list-style-type: none"> <li>• 2 publications</li> <li>• 1 presentation (ASCO GU)</li> </ul>
Ali Golshayan	2007-2008	Faculty, Medical Univ. of South Carolina	<ul style="list-style-type: none"> <li>• 5 publications (<i>JCO, other</i>)</li> <li>• 2 presentations (ASCO GU oral, KCA)</li> </ul>
Saby George	2007-2008	Faculty, Roswell Park Cancer Institute	<ul style="list-style-type: none"> <li>• 3 publications</li> <li>• 5 presentations (KCA, ASCO, ASCO GU merit award)</li> </ul>



Ila Tamaskar	2007-2008	Staff, CCF	<ul style="list-style-type: none"> <li>• 2 publications (<i>JNCI, JUrol</i>)</li> <li>• Presentation (ASCO)</li> </ul>
Anita Schwandt	2008-2009	Fellow in Oncology, University Hospitals	<ul style="list-style-type: none"> <li>• Poster presentation ASCO GU 2009</li> </ul>
Ivan Zama	2008-2009	Palliative care private practice	<ul style="list-style-type: none"> <li>• Publications (<i>Cancer</i>)</li> </ul>
Naveen Basappa	2009-2010	Faculty, University of Toronto	<ul style="list-style-type: none"> <li>• Publications (<i>Cancer</i>)</li> <li>• Poster presentation ASCO GU 2010</li> </ul>
Leticia Varella	2009-2010	H/O Fellow, CCF	<ul style="list-style-type: none"> <li>• Publications</li> </ul>
Mohamed Salem	2010 - 2011	Faculty, Georgetown	<ul style="list-style-type: none"> <li>• ASCO GU 2011 oral presentation</li> </ul>
Yaser Al-Marrawi	2010 - 2011	Fellow, Penn State	<ul style="list-style-type: none"> <li>• Publications</li> </ul>
Housam Haddad	2011 - 2012	Hematology/Oncology Fellowship Staten Island University Hospital-North Shore	<ul style="list-style-type: none"> <li>• Publications</li> </ul>
Khaled Ali	2011 - 2012	Geriatrics Fellowship Thomas Jefferson University Hospital	<ul style="list-style-type: none"> <li>• Publications</li> </ul>
Namita Chittoria	2012-2013	Assistant Professor, SUNY Upstate Medical University	<ul style="list-style-type: none"> <li>• ASCO 2013 Merit Award</li> </ul>
Adriana Alvarez	2013-2014	Oncology Fellow, University Hospitals	<ul style="list-style-type: none"> <li>• KCA presentation</li> </ul>
Christos Kyriakopoulos	2013-2014	Faculty, U Wisconsin	<ul style="list-style-type: none"> <li>• ASCO GU/ASCO posters</li> </ul>
Vijay Damarla	2014-2015	Fellow, Henry Ford	<ul style="list-style-type: none"> <li>• KCA poster/presentation</li> </ul>
Hiral Parekh	2014-2016	Private Practice	<ul style="list-style-type: none"> <li>• KCA poster/presentation</li> </ul>
Arnab Basu	2015-2016	Fellow, USC	<ul style="list-style-type: none"> <li>• Publications</li> </ul>

Pedro Barata	2016 - 2018	Faculty, Tulane	<ul style="list-style-type: none"> <li>• KCA presentation, ASCO/ASCO GU posters, publications</li> </ul>
Prateek Mendiratta	2017-2018	Faculty, UH	<ul style="list-style-type: none"> <li>• KCA presentation, ASCO/ASCO GU posters, publications</li> </ul>

**Internal Medicine Residents**

Juan Barbestefano	2008-2009 / Mentor for Research Elective	CCF Faculty, Internal Medicine	<ul style="list-style-type: none"> <li>• Poster presentation ASCO GU 2009</li> <li>• 1 publication (<i>JUrol</i>)</li> </ul>
Josh Wilfong	2010	Internal Medicine Resident	<ul style="list-style-type: none"> <li>• KCA presentation</li> </ul>
Jonathan Matthias	2012 - present	Internal Medicine Resident	<ul style="list-style-type: none"> <li>• ACS RCC chapter</li> </ul>
Yana Najjar	2012-2014	Faculty, UPittsburgh	<ul style="list-style-type: none"> <li>• ClinSchop mentor, AACR abstract</li> </ul>
Moshe Ornstein	2012 – 2014	Faculty, CCF	<ul style="list-style-type: none"> <li>• KCA oral presentation, ASCO GU poster/Merit Award</li> </ul>

**CCF / CCLCM Medical Students**

Renee Salas	2007-2009 / Mentor for Masters Research Thesis	Resident, U Cincinnati Emergency Medicine	<ul style="list-style-type: none"> <li>• 2 publications</li> </ul>
Bryan Sisk	2009 / Mentor for summer Research project	CCF/CWRU Medical Student	<ul style="list-style-type: none"> <li>• American Cancer Society award</li> <li>• Howard Hughes Medical Institute Research Training Fellowships</li> </ul>
Rita Schlanger	2012 Masters Research Thesis Committee	CCF/CWRU Medical Student	
Frances Mao	2012 Mentor for Masters Research Thesis	CCF/CWRU Medical Student	

Alize Tzeng	Research Advisor	CCF/CWRU Medical Student
-------------	---------------------	-----------------------------

Severine Kako	Research Advisor	CCF/CWRU Medical Student
---------------	---------------------	-----------------------------

Lillian Sun	Research Advisor	CCF/CWRU Medical Student
-------------	---------------------	-----------------------------

Joshua D. Niforatos	Research Advisor	CCF/CWRU Medical Student
------------------------	---------------------	-----------------------------

**International  
Mentees**

Cristina Suarez- Rodruiguez	2012	Faculty, Vall d'Hebron Barcelona, Spain
--------------------------------	------	--

Fernando Sabino	2013	Brazil
-----------------	------	--------

Anna Czarnecka	2012-2013	Poland
----------------	-----------	--------

Carlos Robles Barraza	2014	
--------------------------	------	--

Pedro Barata	2015	Portugal
--------------	------	----------

**CLASSROOM**

1. Annual: CCF Lerner College of Medicine year 2, Course 5 Hematology Curriculum: "Renal Cell Cancer"
2. Dean's Dinner: Lecture and Q/A with 2<sup>nd</sup> year CCLCM student; October 2007

## **REGULAR TEACHING RESPONSIBILITIES**

1. Attending physician, CCF Oncology Service and Oncology Consult Service
2. Preceptor, GU Oncology clinic. Oversee 2 Experimental Therapeutic Fellows each year and 1 Hematology/Oncology Fellow per month
3. Discussant, Hematology/Oncology Journal Club
4. Lectures, Hematology/Oncology Fellowship Educational Curriculum

\*See also seminars and invited lectureships above for CME activity